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AORTIC ROOT ANATOMY
The aortic root is an intriguing part of the heart. It provides the supporting structures 
for the aortic valve leaflets and forms a functional and dynamic connection between 
the left ventricle and the ascending aorta. It is deeply anchored within the central 
base of the heart between the pulmonary root anteriorly and the mitral and tricuspid 
valves posteriorly. Components of the aortic root are the semilunar aortic leaflets, 
the sinuses of Valsalva and the interleaflet triangles. The boundaries of the root are 
formed superiorly by the sinotubular junction and inferiorly by the virtual basal ring 
at the level of the basal attachment points (the nadirs) of the leaflets within the left 
ventricle, as shown in Figure 1 (1-5). The different leaflets and sinuses are distinguished 
by the origins of the left and right coronary arteries. 
Each leaflet contains a hinge point, a body and a coapting free edge with a thickened 
central nodule (nodule of Arantius). The hinge point is a condensation of collagenous 
tissue and is the area where the leaflet is attached to the aortic root. The body is the 
large weight-bearing surface of the leaflet. The free edge of the leaflet is constructed 
so that, when closed, the leaflets coapt over several millimeters. This margin of 
overlap defines the coapting surface of the leaflet. The leaflet itself consists of three 
distinctive connective tissue layers, including the lamina fibrosa on the aortic side, the 
lamina spongiosa in the middle and a thin layer of elastin fibers on the ventricular side 
called the lamina ventricularis (6, 7). The leaflets form a mobile layer of tissue that 
separate the haemodynamic components of the left ventricle and the aorta and are 
attached to the wall of the aortic root in a semilunar fashion. This leaflet attachment 
line has a crown-like shape and the highest points of these attachment lines are at the 
sinotubular junction level forming the commissures (Figure 2). The leaflet attachment 
line constitutes the haemodynamic or physiologic ventriculo-arterial junction. This is 
different from the anatomic ventriculo-arterial junction, which is a virtual horizontal 
circle (basal ring) where the fibro-elastic aortic wall joins the supporting muscular 
structures of the left ventricle at the nadir of the left and right leaflets. Beneath 
the non-coronary leaflet there is no muscular crescent at the base, because it has 
exclusively fibrous walls, the so-called aortic-mitral fibrous continuity.
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Figure 1 (A) The muscular sleeve of the right ventricular outlet (RVOT) has been pulled forward 
to show the left (L) and right (R) aortic sinuses that give origin to the main coronary arteries. 
The non-coronary (N) aortic sinus is furthest from the pulmonary trunk. (B) This overview shows 
the central location of the aortic root and the relationship of the non-coronary aortic sinus to 
the plane of the atrial septum (double-headed arrow). The open arrow indicates the area of 
the aortic mound. MV, mitral valve; TV, tricuspid valve. (C) The aortic root has been opened 
longitudinally to display the level of the sinutubular junction (open arrows), orifices of the 
coronary arteries (small arrows), and the area of fibrous continuity (broken line) between aortic 
and mitral valves. The asterisk marks the pale-coloured area that is the membranous septum. 
(From Ho SY. Eur J Echocardiogr. 2009;10(1):i3-10; reprinted with permission from the author 
and Oxford Journals)
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Figure 2 Diagram of the aortic root. The coronetlike arrangement of the valvar attachments. 
(From Sutton III JP et al., Ann Thorac Surg 1995;95:419-27; reprinted with permission from 
Elsevier)
The sinuses of Valsalva are the expanded portions of the aortic root confined 
proximally by the attachments of the leaflets and distally by the sinotubular junction. 
The sinuses are composed primarily of elastic tissue and support the origins of the 
coronary arteries. They are the anatomical and functional units of the aortic root 
supporting the opening of the leaflets and allowing formation of vortices, which aid 
proper valvular closure and enhance coronary artery perfusion during diastole. An 
interaction of all the components of the aortic root is needed for correct functioning 
of the aortic valve complex, including the sinotubular junction, which is the upper part 
of the sinuses of Valsalva and delineates the beginning of the tubular ascending aorta 
(8-11). The basal parts of the sinuses are separated from each other by the interleaflet 
triangles.
The interleaflet triangles are positioned subvalvularly and are subjected to the 
hemodynamics of the left ventricle. They are triangular extensions of the left 
ventricular outflow tract, which prolong distally to the level of the sinotubular junction. 
The triangles are fibrous areas of the aortic root. The interleaflet triangle between 
the non-coronary and left coronary sinus is part of the area of aortic-mitral fibrous 
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continuity. The triangle between the non-coronary and the right coronary sinuses is 
directly continuous with the membranous part of the ventricular septum. The bundle 
of His lies immediately below the membranous ventricular septum. The last triangle, 
which separates the left and right coronary sinuses, is in continuity with the ventricular 
septum. The interleaflet triangles are crucial for proper valvular function because 
when one or more of the triangles are rudimentary, the valve becomes stenotic (1).
The aortic root is a complex hemodynamic unit. Its components are continuously 
changing and move in harmony during each cardiac cycle. This is due to aortic and 
ventricular pressures and geometry. In vivo studies with tagged radiopaque material 
to ovine and canine aortic roots showed the dynamic nature of the valve complex. 
During systole the diameter of the sinotubular junction increases initially as aortic 
pressure increases, allowing the leaflets to retract and open, and the diameter at the 
base of the leaflets decreases so the root adopts a cylindrical shape. During diastole 
the reverse occurs, the leaflets move towards the ventricle and close so that the root 
geometry changes to a conical shape (8-11).
AORTIC ROOT DISEASE
Aortic aneurysms and dissections are the most common indications for aortic 
root surgery. Pathological aortic leaflets are predominantly treated by aortic valve 
replacement, but when other components of the aortic root are involved, like 
diseased bicuspid aortic valves with a dilated aortic root, aortic root surgery may be 
necessary. Endocarditis of the aortic valve with destruction of the annulus can also be 
an indication for aortic root replacement. There are more pathological conditions of 
the aortic root, but these are less common and will not be discussed here. 
An aneurysm is a dilatation of a blood vessel to more than 1.5 times the diameter 
expected for sex, age, body weight and height (12). An aneurysm of the aortic root 
alone is termed as annulo-aortic ectasia and mainly seen with connective tissue 
disorders (e.g. Marfan syndrome). Most aortic root aneurysms are seen in combination 
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with ascending aorta aneurysms. In the elderly, aneurysms of the ascending aorta 
or aortic root are mainly caused by cystic medial degeneration. In younger patients 
connective tissue disorders, like Marfan syndrome, or a congenital disorder of the 
aortic valve, like a bicuspid aortic valve, are frequently associated with aneurysmal 
dilatation of the aortic root. Most aneurysms are asymptomatic and are diagnosed 
by coincidence. Echocardiography is a frequent mode of diagnosis. Symptomatic 
patients present with chest pain. This is a surgical indication. Size, etiology and growth 
rate determine the surgical intervention moment for asymptomatic ascending aorta 
and aortic root aneurysms. According to guidelines, an asymptomatic degenerative 
aneurysm of the ascending aorta or aortic root with a diameter of 5.5 cm or greater 
should be evaluated for surgery. Patients with connective tissue disorders (e.g. Marfan 
syndrome) or congenital aortic valve disorders (e.g. bicuspid valve) are advised to 
undergo surgery at smaller diameters (4.5 to 5.0 cm) to avoid acute dissection or 
rupture in the future (12).
An aortic dissection is an acute condition with an intimal tear that leads to separation 
of the medial layer of the aortic wall into two layers with the result of a true and 
a false lumen. The true lumen is delineated by the original intimal layer and the 
false lumen is located in the media of the aortic wall. Hypertension, connective 
tissue disorders and cystic medial degeneration are important risk factors for aortic 
dissection. There are two frequently used classifications for dissections, namely the 
DeBakey and the Stanford classifications. The more functional Stanford classification 
is predominantly used in clinics. In Stanford type A, dissection of the ascending aorta 
is involved. Because of intra-pericardial location and the risk of rupture of the aorta in 
the pericardium with acute tamponade, resulting in death, an emergency indication 
for surgical intervention exists. In Stanford type B, the dissection is located beyond 
the left subclavian artery in the descending aorta. Most patients with type A aortic 
dissection have severe chest pain and can be in shock. Untreated type A dissection 
patients have an extremely poor prognosis. If untreated, almost half of the patients 
are deceased within 48 hours. Surgical treatment has the goal of preventing rupture 
by exclusion of the entry tear by replacement. 
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Active endocarditis of the aortic valve is associated with considerable morbidity 
and mortality, especially if there is destruction of the aortic annulus. Fever, heart 
murmur, conduction disorders and embolic manifestations like coronary or systemic 
embolization of vegetations can be present. Clinical suspicion of endocarditis should be 
followed by echocardiography. Most causes of endocarditis are due to staphylococcal, 
streptococcal and enterococcal microorganisms. Antimicrobial therapy is the initial 
treatment after identification of the causative microorganism. In approximately 
half of the patients with endocarditis surgical treatment is necessary. Heart failure, 
uncontrolled infection with perivalvular extension and prevention of embolic events 
(vegetations > 10 mm) are the main indications for surgery (13). The main purpose 
of surgery in active endocarditis is to remove all infected tissue and reconstruct the 
affected area.
AORTIC ROOT REPLACEMENT
There are several surgical options for patients with aortic root disease. Replacement 
of the aortic root and valve with a composite valved graft (conduit) is the most 
common surgical approach. Beside this option, valve-sparing aortic root replacement 
has gained widespread use during the past two decades. The choice of aortic valve 
substitute can be mechanical, biological or, if applicable, the aortic valve leaflets can be 
spared. This choice is made by the patient, the referring cardiologist and the attending 
surgeon and depends on various factors: age, the mental capability and preference 
of the patient (e.g. lifestyle or desire to become pregnant), concomitant disease (e.g. 
atrial fibrillation, dilated poor left ventricle, or already having a mechanical valve), 
the morphology of the aortic valve leaflets and the experience of the surgeon with 
different surgical techniques. 
The mechanical valve was the first aortic valve substitute, the main advantage of 
which was its long durability (14). Mechanical valves, however, require lifelong oral 
anticoagulation therapy to prevent thromboembolic complications. This is a major 
disadvantage, because it is associated with an increased risk of bleeding complications. 
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Oral anticoagulation (i.e. vitamin K antagonists) is difficult to use in clinical practice, 
because it has a slow onset and offset, narrow therapeutic window, variable dose-
response in individuals, and interacts with different food and drugs. These antagonists 
need to be closely monitored for their anticoagulant effect, which is inconvenient for 
patients and costly for health-care systems. The estimated risk of thromboembolism 
after mechanical valve replacement and oral anticoagulation use is 0.2 per 100 patient-
years for valve thrombosis, 1.0 per 100 patient-years for major embolism and 1.8 per 
100 patient-years for all types of embolism with the risk of major bleeding being 1.4 
per 100 patient-years (15, 16). Mechanical valved conduits are not specifically studied 
in this evaluation and are out of the scope of this thesis, since it concentrates on 
biological valved reconstructive surgery of the aortic root. 
Given the fact that the population in the Western World is ageing, it can be expected 
that the percentage of biological solutions for aortic valve and aortic root pathology 
will increase in the future. In fact, the percentage of bioprosthetic valves or biological 
valved conduits implanted in the last decade is increasing, as illustrated in Figure 3 
(17). The biological options discussed in this dissertation are the types of biological 
valved conduits used in the St. Antonius Hospital, Nieuwegein.
the 10 years. Despite these changes, overall mortality fell
for each subgroup. It also fell for most patient subsets out-
lined in Table 5. Subgroup stroke rate also decreased dur-
ing the 10-year period despite increasing age and risk in
this AVR population (Table 5 and Figure 6). To a degree,
stroke and mortality are dependent, because stroke leads to
higher mortality. Nonetheless, for patients younger than 70
years, risk of stroke after AVR was 0.7% in 2006. Be-
tween the ages of 70 and 80 years, stroke rate in 2006
was less than 2.0%, and even for octogenarians, stroke
was less than 2.5% (Table 5 and Figure 6). Stroke rate
in this study was time dependent as well as age dependent.
Female patients had higher mortality, higher stroke rate,
and longer postoperative stay relative to male patients.
This was true for the overall population, the 1997 group,
and the 2006 group. Bridges and coworkers17 previously
demonstrated a relationship between size and outcome in
the STS database in the setting of AVR. Because female
patients have a smaller body size on average than do
male patients, the increased mortality among female pa-
tients is consistent with reports linking body size to out-
come. Factors that cause this effect of higher female
TABLE 3. Relative changes in frequency of selected patient characteristics between 1997 and 2006
Relative change 95% Confidence interval c2 P value
Age 70 y 10.0% 6.4% to 13.6% 31.997 <.0001
Female 0.3% 3.6% to 3.2% 0.025 .87513
Nonwhite 18.0% 2.8% to 35.6% 5.491 .01911
Body mass index 30 kg/m2 37.9% 31.7% to 44.3% 191.399 <.0001
Diabetes 64.6% 55.5% to 74.1% 299.396 <.0001
Type 1 diabetes 38.7% 22.7% to 56.8% 27.376 <.0001
Hypertension 39.3% 35.7% to 43.0% 603.955 <.0001
Nonelective operation 40.8% 20.9% to 64.1% 19.274 .00001
Emergency operation 51.6% 67.6% to27.8% 12.648 .00038
Chronic obstructive pulmonary disease 217.9% 165.0% to 281.5% 154.655 <.0001
Chronic obstructive pulmonary disease in subset 38.8% 23.9% to 55.5% 32.11 <.0001
Peripheral vascular disease 10.9% 3.9% to 27.9% 1.994 .15796
Cerebrovascular disease 63.8% 44.9% to 85.2% 62.422 <.0001
Cerebrovascular accident 15.4% 3.6% to 28.6% 6.729 .00949
Renal failure 36.1% 19.5% to 55.1% 21.581 <.0001
Dialysis 26.0% 0.9% to 57.3% 4.168 .04121
Immunosuppressant medication 47.2% 19.2% to 81.7% 12.913 .00033
Previous coronary artery bypass grafting 60.4% 45.0% to 77.5% 83.535 <.0001
Previous valve surgery 24.5% 32.6% to15.3% 23.248 <.0001
Previous myocardial infarction 25.4% 10.0% to 43.0% 11.433 .00072
Myocardial infarction within 21 d 19.1% 18.8% to 74.6% 0.799 .37146
Congestive heart failure 18.2% 23.9% to12.1% 29.7 <.0001
Angina 3.2% 5.6% to 12.7% 0.476 .49024
Arrhythmia 25.6% 31.3% to19.5% 53.366 <.0001
New York Heart Association functional class IV 38.1% 47.1% to27.4% 35.059 <.0001
New York Heart Association functional class IV in subset 47.2% 55.5% to37.2% 52.569 <.0001
Ejection fraction<30% 2.3% 15.9% to 13.6% 0.09 .76396
Ejection fraction<30% in subset 9.3% 24.1% to 8.2% 1.176 .27826
Aortic stenosis 11.2% 8.2% to 14.4% 55.839 <.0001
Aortic insufficiency 20.3% 11.9% to 29.3% 25.148 <.0001
Aortic insufficiency in subset 4.7% 14.6% to 6.4% 0.723 .39503
Mechanical valve 58.8% 61.8% to55.7% 549.909 <.0001
Bioprosthetic valve 79.7% 67.6% to 92.6% 273.527 <.0001
FIGURE 1. Percentage use of bioprosthetic valves relative to mechanical
valves from 1997 through 2006. Bioprosthetic valve use increased progres-
sively during 10 years. Asterisk indicates P< .000001.
Brown et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 87
A
C
D
Figure 3 Percentage use of biopr sthetic valv s relati  to mechanical valves from 1997 through 
2006. Bioprosthetic valve use increased progressively during 10 years. Asterisk indicates 
P<.000001. (From Brown JM et al., J Thorac Cardiovasc Surg 2009;137:82-90; reprinted with 
permission from Elsevier)
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Homograft
In 1962 Donald Ross and Brian Barrat-Boyes reported independently the clinical use 
of a donor aortic valve homograft (allograft) in an orthotopic subcoronary position 
(18, 19). Ever since, several changes have taken place with the use of homografts. 
The subcoronary technique was initially used to implant the homograft in the aortic 
position, whereby the homograft valve was sewn directly into the aortic root. Because 
of some extensive aortic root pathology expanding beyond the aortic valvular leaflets, 
a full aortic root replacement was introduced, in which the complete homograft aortic 
root is implanted as a functional unit for left ventricular outflow tract reconstruction 
with reimplantation of the coronary arteries (20-22). This technique has advantages 
over subcoronary implantation, since the homograft is less likely to be distorted. 
Matching the homograft size to the host annulus is less critical and is a well-tried, 
accepted technique (23). 
The homografts are usually preserved as a complete aortic root. This includes the 
aortic valve, the muscular part of the left ventricular outflow tract, the anterior leaflet 
of the mitral valve and the ascending aorta together with the aortic arch (Figure 
4). All these tissues may be applicable, depending on the morphological pathology 
that is encountered during surgery. In general, a homograft aortic root replacement 
is considered in aortic valve endocarditis (native and prosthetic) and all aortic valve 
replacements and left ventricular outflow tract reconstructions where anticoagulation 
is undesirable (e.g. children and young adults, women of child-bearing age). Homografts 
have a superior hemodynamic performance, are permeable to serum antibiotics and 
therefore relatively resistant to endocarditis, have very rare thrombo-embolic events 
and do not require long-term anticoagulation (20, 24-26). The initial results with 
cryopreserved homografts are good (27). In Chapter 2 the mid-term results after full 
root replacement with cryopreserved aortic homografts will be evaluated.
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Figure 4 
 
Figure 4 Cryopreserved Homograft
Ross
The use of the autologous pulmonary valve (autograft) to replace the diseased aortic 
valve and a reconstruction of the right ventricular outflow tract with a pulmonary 
homograft was first described by Donald Ross in 1967 (28). The morphology and 
function of the aortic and pulmonary valves are similar. The trileaflet pulmonary valves 
are supported throughout the circumference by the musculature of the infundibulum 
and by the three sinuses of the pulmonary trunk, which interdigitate with the fibrous 
extension of the outflow tract as a consequence of the semilunar attachment of 
the leaflets. This semilunar ventriculo-arterial junction resembles the aortic root, 
but the main difference is the lack of an anatomic ventriculo-arterial junction, the 
relatively thin infundibular muscle compared to thick left myocardium and the lack of 
a sinotubular junction. 
Initially the subcoronary implantation technique was used to implant the pulmonary 
autograft, but after relatively high reoperation rates for severe regurgitation, the 
autograft aortic full root replacement with reimplantation of the coronary arteries 
was introduced, also known as the modified Ross procedure (29, 30). This is the 
favoured technique for implanting a pulmonary autograft in the aortic position and a 
cryopreserved homograft in the pulmonary position. 
The advantages of the pulmonary autograft include the increased cellular viability, 
the growth potential in children, the avoidance of life-long oral anticoagulation, 
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superior hemodynamic performance and rare thromboembolic events (31). The 
modified Ross procedure implies a double valve replacement in patients with 
univalvular disease, which makes the operation technically more demanding and 
requires more experience from the surgeon. The modified Ross procedure is currently 
considered in children and young adults in whom oral anticoagulation is undesirable. 
Contraindications to this operation exist in patients with connective tissue disorders 
or patients with anatomic or structural defects of the pulmonary valve.
Since 1990 the modified Ross procedure has been offered to young adults in the St. 
Antonius Hospital, Nieuwegein. The initial report of aortic root replacement with 
the pulmonary autograft is promising (32). The mid-term results with the use of the 
pulmonary autograft in the aortic position and a homograft in pulmonary position 
are evaluated in Chapter 3. Chapter 4 illustrates a rare complication after pulmonary 
autograft implantation in a young patient.
Valve-sparing Aortic Root Replacement with the Reimplantation technique
After attempts to repair regurgitant aortic valves in the early years of cardiac surgery, 
valve-sparing aortic root replacement techniques for aortic valve regurgitation 
regained interest in the eighties and nineties (33-36). These procedures evolved 
during the years and are nowadays classified as a remodeling (Yacoub) and a 
reimplantation (David) technique (35, 36). The different modifications of valve-
sparing aortic root replacement have been classified by Miller as follows: David-I is 
the original reimplantation procedure using a cylindrical tube graft, David-II is the 
original Yacoub remodeling procedure, David-III is the remodeling procedure with an 
external narrowing annuloplasty strip, David-IV is reimplantation using a 4-mm larger 
graft size with plication of the graft circumferentially at the sinotubular junction above 
the tops of the commissures, and David-V is reimplantation using an even larger graft 
size, which is ‘necked down’ at both the bottom and the top ends to create graft 
pseudosinuses (37). 
In the remodeling procedure the scalloped graft is sewn to residual aortic sinus 
tissue around the aortic leaflets and commissures proximally. This procedure employs 
2 aortic suture lines. The advantage of the remodeling approach is that the graft 
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billows, thereby mimicking the natural sinuses of Valsalva. Conversely, the drawback 
of the remodeling procedure is the absence of fixation of the ventriculo-aortic 
junction, which can predispose to postoperative annular dilatation and recurrent 
aortic regurgitation.
The reimplantation method preferred in the St. Antonius Hospital, is the initial David-I 
method in which the proximal suture technique consists of suturing the proximal graft 
with interrupted, horizontal mattress sutures through the left ventricular outflow 
tract and continuous sutures in a scalloped fashion immediately above the insertion 
of the aortic leaflets. This is the predominantly used method of valve-sparing aortic 
root replacement for different aortic root pathology with preserved, morphologically 
normal aortic leaflets in the St. Antonius Hospital. The advantage of the reimplantation 
approach is that this method firmly anchors the aortic graft proximally at the 
ventriculo-aortic junction below the leaflets with the commissures sewn inside the 
Dacron graft. The preliminary results of valve-sparing aortic root replacement using 
the reimplantation technique are promising (38). In Chapter 5 the mid-term results 
of valve-sparing aortic root replacement with the reimplantation technique are 
evaluated. Chapter 6 describes a rare traumatic lesion of the aortic valve that is solved 
by valve-sparing repair of the leaflet.
Biological Valved Conduits
The first complete replacement of the aortic root with a conduit was in 1968 and 
contained a mechanical valve sutured to the end of a Teflon aortic prosthesis (39). 
The so-called inclusion or wrap technique was used to implant the conduit for aortic 
root reconstruction. The appreciation of false aneurysms arising at the side to side 
coronary ostial or distal aortic anastomosis caused this technique to evolve over the 
years to the button technique. Here, the coronary ostia are dissected as buttons, 
preserving 5 to 6 mm of native aortic wall, and reimplanting in an end to side fashion 
to the aortic graft (40, 41). The button technique, also known as the modified Bentall 
procedure, is the favoured method for aortic root reconstruction.
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Biological valved conduits are nowadays commercially available as substitutes for 
aortic root replacement. These are readily available in all sizes and do not need 
lifelong oral anticoagulation. Since the nineties many companies began offering 
biological valved conduits to the market e.g. Medtronic Freestyle (Medtronic, Inc., 
Minneapolis, MN, USA ), Toronto stentless root (St. Jude Medical, Inc., St. Paul, MN, 
USA) or Edwards prima plus stentless root (Edwards Lifesciences, Corp., CA, USA). Over 
the years two biological valved conduits have been used primarily in the St. Antonius 
Hospital, Nieuwegein, namely the Shelhigh BioConduit model NR-2000C (Shelhigh, 
Inc, Milburn, NJ, USA) and the BioValsalva Conduit (Vascutek Terumo, Renfrewshire, 
Scotland).
Shelhigh BioConduit model NR-2000C is a bovine pericardial straight graft with an 
incorporated porcine stentless valve, which is treated with the No-React process 
(Figure 5). This No-React xenograft pre-treatment involves aldehyde cross-linkage to 
achieve high resistance to biodegradation, an aldehyde detoxification process, and 
surface modification with a surfactant (42). This method seems to have beneficial 
properties above the standard treatment of fresh bioprosthetic leaflet materials of 
either bovine pericardium or porcine aortic valve with glutaraldehyde (43). Chapter 7 
evaluates our initial experience with the use of the Shelhigh BioConduit.
 
 
 
Figure 5 
 
Figure 5 Shelhigh BioConduit model NR-2000C
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The BioValsalva conduit is a combination of a Valsalva graft and a stentless porcine 
valve (Elan, Vascutek, Terumo) (Figure 6). The coated polyester (Dacron) Valsalva 
graft has to be stored in a dry environment and the biological valve must be stored 
in glutaraldehyde. This problem is solved by modifying the coated polyester Valsalva 
graft into a 3-layered graft, which allows storage in glutaraldehyde and preserves 
its impermeability. This vascular graft is made of an uncoated Gelweave (Vascutek, 
Terumo) polyester inner layer and a polytetrafluoroethylene outer layer, which are 
glued together with a central, self-sealing elastomeric membrane that makes the graft 
impermeable (44). The proximal part of the graft has the Valsalva shape, mimicking 
the sinuses of the aortic root with reduction of tension on the coronary buttons and 
improvement of coronary flow and valve hemodynamics (45, 46). In Chapter 8 our 
experience with the BioValsalva conduit is described.
Figure 6 BioValsalva Conduit
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AIM OF THE THESIS
This thesis presents the results of different biological valved conduits for aortic root 
surgery, performed in the St. Antonius Hospital in Nieuwegein. The aim is to evaluate 
hospital outcomes and follow-up results. Based on this, the following research 
questions will be explored in the corresponding chapters: 
•	 Do the mid-term follow-up results support the use of cryopreserved 
homografts for endocarditis and in relatively young patients who do not 
want to use anticoagulation (Chapter 2)?
•	 Is the modified Ross procedure still an option for young adults who prefer 
not to use anticoagulation (Chapter 3 and 4)?
•	 Does the mid-term evaluation of valve-sparing aortic root replacement 
using the reimplantation technique encourage its application (Chapter 5 
and 6)?
•	 What are the initial results with commercially available biological valved 
conduits (Shelhigh bioconduit and Biovalsalva conduit) (Chapter 7 and 8)? 
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ABSTRACT
Background. Aortic root replacement with aortic homografts for various pathologic 
conditions involving the aortic root has yielded good early results. To assess mid-term 
valve-related events, a follow-up study was conducted.
Methods. From February 1989 through January 2003, 213 patients with a mean 
age of 51.3 ± 11.8 years underwent aortic root replacement with a cryopreserved 
aortic homograft. Bacterial endocarditis (58.7%) was the predominant indication for 
surgery (native valve endocarditis, n = 73; prosthetic valve endocarditis, n = 52). Of 
the 197 hospital survivors, 194 were entered in the follow-up study (98.5% complete). 
Endpoints of the study were death, valve-related death, reoperation for valve failure, 
endocarditis, thromboembolic events and anticoagulant-related bleeding events. 
Follow-up was conducted between February and April 2003.
Results. Overall hospital mortality was 7.5% (n = 16; 70% confidence limits, 5.6% 
to 9.4%). Mean follow-up was 5.8 years (range, 0.3 to 14.3). In total, 20 late deaths 
occurred (10.3%); of these, 5 were valve-related. The overall survival at 5 and 10 
years is 87.3% ± 2.4% and 70.8% ± 5.3%, respectively. Twenty-one patients (10.8%) 
required reoperation, either for structural valve deterioration (n = 12), false aneurysm 
(n = 3), endocarditis of the homograft (n = 3), or for other reason (n = 3). Mortality 
for reoperation was 28.6% (n = 6). Five-year and 10-year freedom from reoperation 
is 94.5% ± 1.8% and 76.4% ± 5.3%, respectively. Endocarditis of the homograft was 
reported in 4 patients (3.2%), of whom 1 patient was treated medically and 3 required 
reoperation. Thromboembolic events (n = 1) and anticoagulant-related bleeding 
events (n = 0) were rarely seen. A recent echocardiographic study was available in 
124 patients (71.3%). Aortic regurgitation grade I to II was reported in 121 patients 
(97.6%).
Conclusions. Cryopreserved aortic homografts function well on mid-term evaluation. 
The incidence of structural valve failure is acceptable. Reoperations for homograft 
endocarditis carry a high mortality rate.
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INTRODUCTION
Since the publications on the clinical use of homografts for aortic valve replacement, 
human tissue valves formed their own position in the era of aortic valve substitutes 
(1,2). As with every valve substitute, the homograft aortic valve has its advantages 
and disadvantages. Restoration of normal flow in the aortic root and coronary 
orifice resulting in better hydraulic performance, resistance to endocarditis and 
rare thromboembolic events without the need for anticoagulation are considered 
as advantages. Limited donor availability and homograft durability are the serious 
disadvantages. The long-term performance of homograft aortic valves is profoundly 
influenced by sterilization and preservation. Early methods like chemical preservation, 
irradiation (3-5) and freeze drying (6,7) have shown profound deleterious effect on 
the long-term function of the aortic homografts. The method of preservation that is 
currently used in most centres is the technique of homograft valve cryopreservation 
(8,9). It has the advantage of a long shelf half-life time and is readily available for use.
After yielding good early results with cryopreserved aortic homografts used as a 
freestanding aortic root replacement (10), the present purpose is to asses the mid-
term valve-related events in a retrospective follow-up study.
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MATERIAL AND METHODS
Patients
From February 1989 through January 2003, 213 patients with a mean age of 51.3 
± 11.8 years (range 14 to 79) underwent aortic root replacement (ARR) with a 
cryopreserved aortic homograft. There were 159 (74.6%) male and 54 (25.4%) female 
patients. The indication for operation was aortic regurgitation in 172 patients of which 
125 cases were due to endocarditis (73 native valve endocarditis versus 52 prosthetic 
valve endocarditis), aortic stenosis in 27 patients, and mixed lesions in 14 patients. 
Pertinent patient data are given in Table 1.
Table 1. Preoperative and Perioperative Patient Characteristics (n=213)
Age (years)
    mean (SD;range) 51.3 (11.8;14-79)
Gender (M/F ratio) 159/54
NYHA class
    I 21 ( 9.9%)
    II 72 (33.8%)
    III 77 (36.2%)
    IV 43 (20.1%)
Indication
•	 regurgitation 172 (80.8%)
1. endocarditis 125 (72.7%)
            -native valve   73 
            -prosthetic valve   52 
2. non-endocarditis   47 (27.3%)
•	 stenosis   27 (12.7%)
•	 mixed lesion   14 (  6.5%)
Type of previous cardiac surgery (n=75)
     coronary bypass   8 ( 9.7%)
     valve operation 51 (62.2%)
     combination 19 (23.2%)
     other   4 (  4.9%)
Elective/urgent operation ratio 180/33
Concomitant procedure (n=44)
     coronary bypass planned 12 (26.1%)
     MVP/R 13 (28.2%)
     coronary bypass unplanned   5 (10.9%)
     other 16 (34.8%)
SD = standard deviation; NYHA = New York Heart Association; MVP/R = mitral valve plasty/
replacement
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Homograft Data
Aortic homograft valves were harvested under sterile conditions from cardiac 
transplant recipients, beating-heart or nonbeating-heart donors, with a maximum 
age of 60 years. Dissection of the heart was generally performed within 24 hours after 
circulatory arrest. After dissection, the valves were decontaminated by incubation 
in medium with an antibiotic mixture for 5 hours at 37°C. Thereafter, valves were 
cryopreserved in medium containing 10% dimethylsulfoxide (DMSO) frozen at a 
controlled rate of -1°C/min up to -100°C and stored on the vapor of liquid nitrogen 
(-150° to -196°C). All tissues were cryopreserved within 50 hours after circulatory 
arrest of the donor. All donors were seronegative for human immunodeficiency virus, 
hepatitis B surface and core antigen, cytomegalovirus or Treponema pallidum. For 
implantation, ABO compatibility or HLA type matching was not required. In elective 
operations, mismatch in age of more than 10 years between the donor valve and 
recipient was avoided; in urgent operations this was possible only occasionally. All 
homografts were provided by Bio Implant Services Foundation (BIS, Leiden, the 
Netherlands). The homograft characteristics are displayed in Table 2. Details on the 
operative technique were described before (10).
Table 2. Cryopreserved Aortic Homograft Characteristics (n=213)
Diameter (mm)
    mean (SD) 24.0  (1.1)
    < 23      24    (11.3%)
    23 – 25 156  (73.2%)
    > 25      33    (15.5%)
Donor Age (years)
    mean / median (SD;range) 44.5 / 46.0 (11.0;13-60)
Donor-recipient age mismatch (years)
    mean / median (SD;range) 7.1 / 5.5 (17.7; 30-58)
SD = standard deviation
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Follow-up
Recent information (less than 6 months) about the status of all hospital survivors 
is collected from the referring cardiologist, by visit at our cardiology department, 
or by their general physician. April 30, 2003, was the closing date for follow-up and 
included physical examination, echocardiography, and chest radiography. Endpoints of 
the study were death, valve-related death, reoperation for valve failure, endocarditis 
of the homograft, thromboembolic events, and anticoagulant-related bleeding. 
These endpoints were defined according to the guidelines reported by Edmunds 
and associates (11). Valve function was determined by echocardiographic Doppler 
study including colour-flow mapping, as much as available, otherwise by auscultation. 
Homograft regurgitation was graded on a scale of 0 to 4 on echocardiography, with 0 
as no regurgitation, 1 as trivial regurgitation, 2 as mild regurgitation, 3 as moderate 
regurgitation and 4 as severe regurgitation. 
Data Analysis
Retrospective review was done on the data of all consecutive patients who underwent 
homograft ARR. Quantitative data are presented as mean ± standard deviation. 
Univariate comparisons between groups were calculated by the unpaired test, Fisher’s 
exact test, c² test, or the one-way or two-way analysis of variance as appropriate. All 
probabilities are two-tailed. Kaplan-Meier survival curves were used for analysis of 
survival times, and Tarone or Breslow test for comparisons between survival curves. 
Precision was indicated by 70% confidence limits (CL).
RESULTS
Patient Survival
Hospital mortality was 7.5% (n=16; 70% CL, 5.6% to 9.4%). There were 197 hospital 
survivors, of whom 194 were entered in the follow-up study (98.5% complete). Mean 
and median follow-up times were 5.8 years and 5.4 years, respectively (range 0.3 to 
14.3 years). Total follow-up was 1118 patient-years. Three patients were lost to follow-
up, 2 patients due to emigration and 1 patient moved to an unknown address. During 
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follow-up 20 patients (10.3%) died. Five of these late deaths were valve-related. Three 
patients had endocarditis of the homograft, 1 had structural valve deterioration and 
1 patient had a false aneurysm. All valve-related late deaths were reoperated on. Of 
the other 15 non-valve related late deaths 4 patients died of cardiac failure (heart 
failure and one myocardial ischemia 79 months postoperatively) and 11 patients died 
of noncardiac causes. This is summarized in Table 3. The overall survival at five and ten 
years is 87.3% ± 2.4% and 70.8% ± 5.3% respectively. Survival at five and ten years for 
the endocarditis group was 82.7% ± 3.6% and 57.1% ± 9.9% respectively, and 91.3% ± 
3.7% and 84.3% ± 5.9% for the non-endocarditis group. This is presented in Figure 1.
Table 3. Late Deaths (n=20)
Valve-related Nonvalve-related
- endocarditis 3 - cardiac 4
- structural valve disease 1 - noncardiac 11
- false aneurysm 1              pulmonary 4
             neurologic 1
             cancer 1
             unknown 5
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Figure 1 Survival curve after homograft aortic root replacement. Open circles = nonendocarditis 
group; solid circles = overall group; triangles = native valve endocarditis/prosthetic valve 
endocarditis group.
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Reoperation
Twenty-one patients (10.8%) required reoperation for significant homograft valve 
dysfunction due to structural valve deterioration (n=12), false aneurysm (n=3), 
homograft valve endocarditis (n=3) or other reason, as displayed in Table 4. Mean 
length of time between the initial ARR and reoperation was 67.8 months ± 41.6 
months. Six patients reoperated on for structural valve deterioration received an aortic 
valve replacement (mechanical prosthesis, n= 5; biological prosthesis, n= 1), 3 patients 
had a Bentall procedure, 2 patients an aortic valve and supracoronary ascending aorta 
replacement, and 1 patient had a second homograft implantation. Patients reoperated 
on for homograft endocarditis received a second homograft implantation, a Shelhigh 
bioconduit (Shelhigh, Millbum, New Jersey) and mechanical aortic valve replacement, 
respectively. Six patients (28.6%) died after reoperation. Three patients died after 
reoperation for endocarditis of the homograft, 2 patients after reoperation for false 
aneurysm and one patient after reoperation for structural valve deterioration. Three 
of these patients underwent a second or third reoperation. Five- and 10-year freedom 
from reoperation is 94.5% ± 1.8% and 76.5 ± 5.3% as presented in Figure 2.
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Figure 2 Freedom from reoperation after homograft aortic root replacement, overall group.
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Table 4. Indication for Reoperation (n=21)
- structural valve disease 12
- false aneurysm 3
- endocarditis homograft 3
- coronary sclerosis 1
- mitral valve regurgitation 1
- pericarditis constrictiva 1
Endocarditis
Endocarditis of the homograft valve was reported in 4 patients (3.2%) of whom one 
was treated with antibiotics for 6 weeks, and three required reoperation. The medically 
treated patient recovered completely, but all patients reoperated on for endocarditis 
of the homograft died soon after the reoperation. The indication for the initial ARR 
was native valve endocarditis for 3 patients and prosthetic valve endocarditis for 1 
patient. The recurrent endocarditis developed 4, 20, 92, and 114 months after the 
initial operation. The microorganism initially found in the blood culture was different 
in the second blood cultures in all patients with a recurrent endocarditis of the 
homograft. The actuarial freedom from endocarditis of the homograft at 5 and 10 
years was 99.5% ± 0.5% and 93.5% ± 3.5%, respectively.
Structural valve deterioration
Reoperation and replacement of the aortic homograft due to structural valve 
deterioration was reported in 12 patients. Mean length of time between initial ARR 
and reoperation was 75.3 months (range 16 to 121). One patient was in the process 
of evaluation for reoperation due to structural valve deterioration at the end of the 
follow-up period. One patient died after reoperation for structural valve deterioration. 
Actuarial freedom from structural valve deterioration at 5 and 10 years was 98.1% ± 
1.1% and 85.8% ± 4.5%, respectively.
Thromboembolism
One patient developed thromboembolism resulting in stroke with permanent sequel 
after 61 months of the initial operation. Like thromboembolism, anticoagulant-related 
bleeding events (n=0) were rarely seen.
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Other complications 
During follow-up 22 patients needed a definitive pacemaker.
Homograft valve function
Echocardiographic evaluation of the homograft function was performed by most 
cardiologists when there was a clinical indication. Otherwise, this study was repeated 
once in 24 months, approximately. A recent echocardiographic evaluation is defined 
as an echocardiographic study within 24 months before April 30, 2003, the closing 
date for follow-up. A recent echocardiographic assessment of the homograft valve 
function was available in 124 patients (71.3%). Data from this evaluation are listed in 
Figure 3. There was 1 patient in the follow-up group period of 0 to 3 years, who had a 
grade III aortic regurgitation. This patient had no complaints and the clinical situation 
was acceptable. The follow-up group period of 4 to 6 years had a predominantly 
favourable result. Most patients with a severe grade III or IV aortic regurgitation were 
in the group with the longest follow up. All these patients were in the evaluation for a 
reoperation. Also the percentage of grade II aortic regurgitation was increasing.
Figure 3  
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Figure 3 Echocardiographic data: aortic regurgitation during follow-up. Open bars = trivial; light 
shaded bars = mild; dark shaded bars = moderate; black bars = severe. (yrs = years.)
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DISCUSSION
Since the beginning of homograft aortic valve replacement in our centre, the 
freestanding aortic root replacement has been the technique of choice for the 
reasons previously described (10). In brief, being a geometrically single functional unit 
of the homograft at the implantation, it is expected to reduce both early and late 
postoperative regurgitation (12,13). More than half of the patients in our series had 
active endocarditis (n=125) and we believe that in such complex aortic root disease 
the aortic root replacement technique offers additional advantages because it can 
fill subannular defects with the muscular cuff of the soft annulus and help restore 
atrioventricular continuity. More recently, however, we would also consider implanting 
a biological valve conduit in aortic valve endocarditis (14). The rationale is based on 
several observations. Firstly, the promising initial results with the conduit. Secondly, 
these valves are readily available on the shelf in all seizes, so the operation can be 
performed immediately if necessary. Finally, the overall results from our series for 
reoperations on the homograft root are disappointing: a reoperation on the calcified 
homograft root is not only challenging for the surgeon, but also especially for the 
patient. 
At the evaluation of results of homograft series one must clearly identify whether 
viable or nonviable valves are being implanted; and when fresh valves are used, how 
fresh they are, as was pointed out by O’Brien and associates (9). According to this, we 
have good results of the cryopreserved homografts comparable to those described in 
other series (15-19). Overall survival at 10 years was 70.8%, similar to the 73% survival 
at 9 years demonstrated by Takkenberg and associates (15), 74% survival at 10 years 
reported by Doty and associates (16) and 85 % survival at 8 years in the series of 
Kirklin and associates (17).
Cryopreserved aortic homograft demonstrates excellent freedom from throm-
boembolism in this series. In the first three months postoperative acenocoumarol is 
the choice of oral anticoagulation. After this period, it is switched to acetylsalicylic 
acid. Only one thromboembolic event was reported on a mean follow-up of 5.8 years. 
It is not clear whether this extremely low rate is reliable. Usually very little information 
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on minor thromboembolic events is available, be it from the patient or from the 
patient’s physician. On the other hand, important thromboembolic events tend to be 
well documented. Anyway, the overall low incidence of thromboembolic events in our 
series confirms the findings of other groups. Endocarditis of the homograft developed 
in 4 patients of which 3 were reoperated on, and one patient was medically treated. 
Doty and associates (16) reported only one case of homograft endocarditis in 117 
patients. In their series only 15 (13%) patients had clinical evidence of aortic valve 
endocarditis, compared to 125 (58.7%) patients with aortic valve endocarditis in our 
series. Kirklin and associates (17) reported 3 cases of endocarditis of the homograft 
in 178 patients followed up for 9 years. Endocarditis was reported as preoperative 
indication in 41 patients (23%) in their series.
To date, with a mean follow-up of 5.8 years there was structural valve deterioration 
reported in 12 patients. The freedom from structural valve deterioration at 5 years 
in our series is acceptable and similar to other comparable studies (15-18). From our 
results, structural valve degeneration occurred early (less than 5 years) in 4 patients. 
This has influenced considerably our strategy as to which patients should benefit from 
a homograft valve. In the earlier phase of the study, the homografts were offered to 
young adults and patients with endocarditis. Nowadays, in our institution, homografts 
are seldom offered to young adults, but are still considered for endocarditis patients. 
Reoperations for homograft dysfunction carried a high mortality in our series. This 
was particularly so in patients with homograft endocarditis. It has been our strategy to 
remove the complete homograft root at reoperation for endocarditis. This has proven 
to be not the simplest of solutions. Reoperation in the non-endocarditis group had 
a more favourable outcome, because a less aggressive surgery could be performed.
In conclusion, cryopreserved aortic homografts function well on mid-term. The 
incidence of structural valve failure is acceptable. Reoperations for homograft 
endocarditis carry a high mortality.
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ABSTRACT
Background. Pulmonary autograft aortic root replacement was used in adults. Risk 
factors for aortic valve incompetence (AI) and pulmonary homograft valve stenosis 
are indentified.
Methods. From February 1991 through May 2003, 103 patients, with a mean age of 
35.2 ± 9.5 years, underwent aortic root replacement with the pulmonary autograft. 
Annulus reinforcement (reduction annuloplasty or use of root ring) was carried out in 
45 patients. In all but 1 patient, the right ventricular outflow tract was reconstructed 
with a cryopreserved pulmonary homograft. Mean follow-up duration was 6.0 ± 2.8 
years (range 0.3 to 11 years).
Results. There were no hospital deaths. Overall patients survival was 98.9 ± 1 % 
at 1 year and 97.3 ± 1.9 % at 10 years. Autograft function follow-up resulted in 5 
patients requiring reoperation for aortic incompetence. The univariate risk factors 
for aortic incompetence at discharge and during follow-up were respectively annulus 
reinforcement (p=0.05) and bicuspid aortic valve (p=0.05). Reoperation for homograft 
failure occurred in 1 patient. During follow-up, 24 patients (25.5%) developed 
homograft stenosis (gradient > 20 mm Hg). Univariate analysis indicated the diameter 
of the homograft (p=0.001) as factor associated with stenosis during follow-up. Cox 
regression identified smaller diameter of the homograft (p=0.001) and older age 
of donor (p=0.002) as independent risk factor for the development of homograft 
stenosis. 
Conclusions. The Ross operation can be performed with few complications. Although 
both the aortic autograft and the pulmonary homograft have limited durability, this 
has not jet resulted in considerable reoperation rates and associated morbidity and 
mortality.
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INTRODUCTION
Ross introduced the replacement of a diseased aortic valve by means of a pulmonary 
autograft in 1967 (1). Ross’ group identified the advantages of the autograft valve as 
excellent hemodynamic performance, freedom from anticoagulation and, for children, 
the potential for growth. Relatively high mortality, early failure rates reported, and 
the complexity of the procedure have deterred many surgeons from embracing 
this procedure in the past (2, 3). Recent experience, on the contrary, indicates that 
this operation can be performed with acceptable risk (4, 5). This can be explained 
by increasing experience and modification of the surgical technique from an original 
subcoronary technique toward a full root replacement technique (6). This aricle 
describes our medium-term experience with the Ross operation in 103 adult patients 
(with aortic valve disease) and presents the result of serial echocardiographic study 
assessing the function of the autograft and the pulmonary homograft.
PATIENTS AND METHODS
From February 1991 through May 2003, 103 selected adult patients with a mean age 
of 35.2 ± 9.5 years (range 17 to 65 years old) underwent root replacement with the 
pulmonary autograft. The characteristics of the patients are reported in Table 1. 
Our operative techniques for the Ross operation and autograft annulus reinforcement 
and reduction have been previously described (7). Briefly, all operations were 
performed with the use of mild systemic hypothermia; myocardial protection was 
provided by low sodium normopotassic cardioplegic solution and topical cooling. In all 
the patients, the autograft was implanted as a free standing root. The diameter of the 
aortic annulus and pulmonary autograft was assessed by intraoperative measurement 
with cylindrical sizers. In 39 patients (37.8%) the proximal autograft suture line was 
reinforced by a 5-mm large strip of fresh autologous pericardium or prosthetic material 
(Teflon felt (Impra Inc, subsidiary of C.R. Brand, Temple, AZ), or a woven Dacron ring 
(C.R. Brand, Haverhill, PA)). In 12 patients (11.6%), significant dilatation of the aortic 
annulus (diameter exciding the Z + 2 value for the body surface area), required aortic 
Chapter 3
46
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
annulus reduction. It was carried out by placing two 2-0 polypropylene sutures as a 
purse-string in a single horizontal plane just below the aortic annulus (8). Homograft 
reconstruction of the right ventricular outflow tract (RVOT) was accomplished with a 
cryopreserved pulmonary homograft in 102 patients and with a bovine pericardium 
mounted xenograft in 1 patient. All cryopreserved pulmonary homografts were 
provided by Bio Implant Service Foundation (BIS; Leiden, The Netherlands). The 
donors had a mean age of 45.2 ± 12.9 years (range 9 to 66 years old). Concomitant 
procedures included mitral valve plasty in 1 patient and open mitral commissurotomy 
in 1 patient. Mean cardiopulmonary bypass time was 187.8 ± 35.8 min (range 133 to 
287 min) and mean aortic cross-clamp time was 137.6 ± 26.5 min (range 98 to 232 
min).
Table 1. Preoperative Patient Characteristics (n=103)
Age (years)
    mean (SD) 35.2 ± 9.5
Gender (male) 71
NYHA class
    I 59 (57.3%)
    II 27 (26.2%)
    III 17 (16.5%)
    IV -
Left ventricular ejection fraction
    > 50% 68 (66.0%)
    30 – 50% 31 (30.1%)
    ˂ 30%   4 (3.9%)
Predominant lesion
    Aortic stenosis 20 (19.4%)
    Aortic incompetence 51 (49.5%)
    Mixed aortic disease 32 (31.1%)
Aortic valve morphology
     Bicuspid (congenital) 44 (42.7%)
     Tricuspid 59 (57.3%)
Previous aortic valve surgery
    Valve replacement 2 (1.9%)
    Valvulotomy 5 (4.8%)
    Valvuloplasty 1 (0.9%)
    Enucleation of subvalvular membrane 2 (1.9%)
Values are mean ± 1 standard deviation (SD); NYHA = New York Heart Association
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Postoperative Follow-up
Follow up was conducted between June and July 2003 by two investigators and was 
97% complete. The 3 patients, whose follow-up was incomplete, were censored at the 
time of their last follow-up. 
Assessment included New York Heart Asscociation (NYHA) functional class, drug 
therapy, electrocardiogram, chest radiogram and transthoracic M-mode, two 
dimensional and color-flow Doppler echocardiograms. The echocardiographic 
examinations were performed at discharge, 3 to 6 months postoperation, 1 year after 
the operation, and on a regular base thereafter. The mean transvalvular pressure 
gradient of the aortic and pulmonary valves was calculated (9). Color-flow Doppler 
was used to detect aortic and pulmonary valvular incompetence, and severity was 
subjectively graded as trivial (1+), mild (2+), moderate (3+) and severe (4+).
Statistical Analysis
All analyses were performed using SPSS 8.0 for Windows (SPSS Inc, Chicago, IL). 
Continuous variables were expressed as the mean ± standard deviation (SD) and 
were analysed by using the unpaired two-tailed t test. Categorical variables were 
presented as percentage and were analysed with the c2 test or Fischer’s exact test 
when appropriate. Univariate and multivariate analysis was used to study potential 
determinants of aortic valve incompetence (AI) grade 2 or more at discharge. The 
following categorical variables were considered: sex, gender, preoperative AI grade 2 
or more, preoperative left ventricle function less than 40 %, annulus reinforcement 
(reduction annuloplasty or use of root ring), and bicuspid aortic valve. Variables that 
achieved a p value ˂  0.2 in the univariate analysis were examined by using multivariate 
analysis with forward stepwise logistic regression for the developing of AI grade 2 
or more. The same variables analysed for AI at discharge were studied for AI grade 
2 or more during follow-up. Variables that achieved a p value less than 0.2 in the 
univariate analysis were examined by using Cox proportional hazard regression for the 
developing of AI grade 2 or more.
The development of a 20 mm Hg or greater gradient through the pulmonary homograft 
during follow-up was also investigated. For the univariate analysis the following 
variables were considered: diameters of the pulmonary homograft (continuous 
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variable), age of the donor (continuous variable), and donor status ( beating heart, non 
beating heart; categorical variables). Variables that achieved a p value less than 0.2 in 
the univariate analysis were examined by using Cox proportional hazard regression 
for the developing of a 20 mm Hg or greater gradient through the homograft during 
follow-up. Estimates for long-term survival and freedom from morbid events were 
made by the Kaplan-Meier method.
RESULTS
Mean follow-up was 6.0 ± 2.8 years (range 0.3 to 11 years).
Mortality
There were no hospital deaths. There were two late deaths. One patient died from 
bacterial meningitis 1 year postoperatively. The other patient developed pulmonary 
homograft endocarditis (proven by autopsy) 8 years after the operation and died 
acutely. Overall patients survival is shown with the Kaplan-Meier analysis in Figure 1, 
with 98.9 ± 1 % at 1 year and 97.3 ± 1.9 % at 10 years.
Figure 1. Overall patient survival
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Morbidity
Eleven patients (10.7 %) required early reoperation (<24 hours) for bleeding. Four 
patients (3.9 %) developed myocardial infarction (creatinine phosphokinase > 300 
IU/L, myocardial band > 5 %); 2 of them underwent coronary angiography that 
revealed a stenosis of the reimplanted right coronary ostium; the lesion was treated 
in both cases with a stent implantation. Both interventions were done within the same 
admission, a few days after surgery. The other two patients refused to undergo the 
coronary angiography, and are actually in NYHA class I. Three patients underwent 
pacemaker implantation because of permanent atrioventricular block. Two of these 
patients had extensive annular calcification, and 1 patient was a reoperation.
Reoperations for Autograft Failure
Five patients (4.8 %) have required reoperation on the autograft valve for 
incompetence. Two patients developed severe aortic incompetence respectively 6 
weeks and 15 months after the Ross procedure. In the first patient the pulmonary 
autograft was quadricuspid and this congenital anomaly was detected only at the end 
of the initial operation. In the second patient the cause of the autograft failure was 
unclear. In both cases a mechanical prosthesis was implanted within the autograft. 
Another patient has undergone aortic valve replacement 4 years after the operation 
for progressive autograft incompetence due to annular dilatation. The remaining 2 
patients were reoperated respectively 3 and 8 years after the initial operation for a 
dilatation of the autograft root at the sinotubular level and severe AI detected by 
echocardiogram; in both cases a mechanical composite graft was implanted. Freedom 
(Kaplan-Meier) from reoperation on pulmonary autograft is 98.7 ± 1.2 % at 5 years, 96 
± 2.9 % at 7 years, and 87.4 ± 6.4 % at 10 years (Fig 2).
Reoperations for Pulmonary Homograft Failure
Reoperation for homograft failure occurred in 1 patient; he developed stenosis of the 
pulmonary homograft (pulse Doppler gradient of 50 mm Hg) 13 months after the 
initial operation. The patient, initially treated with patch angioplasty of the pulmonary 
homograft, had replacement of the homograft 3 years postoperatively. Freedom from 
reoperation on pulmonary homograft is 98.7 ± 1.2 % at 10 years.
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Figure 2. Actuarial freedom from reoperation on pulmonary autograft during follow-up.
Valvular Endocarditis
Endocarditis occurred in 2 patients. In the first patient the endocarditis was localised 
on the pulmonary autograft and was successfully treated with antibiotics; a recent 
echocardiogram of the patient depicts a trivial aortic incompetence. In the second 
patient, as already described, the endocarditis was localised on the pulmonary 
homograft and was fatal. Freedom from endocarditis is 98.3 ± 1.6 % at 6 years and 
95.7 ± 3 % at 10 years.
Cerebrovascular Accident
Three patients had cerebrovascular accident (CVA) 9 months, 4 years, and 5 years 
postoperatively, respectively. There was no documented arrhythmia or clot in the 
heart on echocardiography. Freedom from CVA is 96.7 ± 2.2 % at 6 years and 92.5 ± 
4.6 % at 10 years.
When including death of any cause, reoperation, CVA and endocarditis as events, the 
event-free survival at 1 year is 98.9 ± 1 %, 96.3 ± 2 % at 5 years, 85.5 ± 5.4 at 8 years, 
and 75.4 ± 7.3 at 10 years (Fig 3).
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Figure 3. Event-free survival.
Autograft Valve Function
All the patients underwent two-dimensional echocardiogram at discharge. There was 
no aortic incompetence (AI) in 69 patients (67.0 %), 30 patients (29.1 %) had a trivial AI; 
3 (2.9 %) had a mild AI, and 1 (1.0 %) had severe AI requiring reoperation 6 weeks after 
the Ross procedure. The influence of the variables including sex, gender, preoperative 
AI grade 2 or more, preoperative left ventricular function, bicuspid valve, annulus 
reinforcement (reduction annuloplasty or use of root ring) on the incidence of early 
AI grade 2 or more (only 4 patients) was investigated. Regurgitation was central in the 
majority of patients. At the univariate analysis, annulus reinforcement (p = 0.05) was 
the only factor associated with AI grade 2 or more at discharge. Multivariate analysis 
failed to show any significant independent risk factor, but numbers in the subgroups 
were small. 
Recent echocardiographic assessment (within 1 year of closing date of the follow-up 
study) of the pulmonary autograft valve function was available in 73 % of patients 
(excluding 2 deaths and 5 reoperations); in 85 % of patients, an echo of less than 
2 years old was available. All patients without recent echocardiographic assessment 
have stable clinical examination. Details are listed in Table 2. None of the patients had 
aortic valve stenosis. The number of patients with AI grade 2 or more was significantly 
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(p = 0.03) higher during follow-up compared to discharge (4 of 103 at discharge and 
18 of 94 during follow-up). The same variables analysed for their influence on AI at 
discharge were studied for their influence of AI grade 2 or more during follow-up. At 
the univariate analysis, bicuspid aortic valve (p = 0.05) was the only factor associated 
with AI grade 2 or more during follow-up. Cox proportional hazards regression failed 
to show any significant independent risk factor. Freedom from mild or more AI was 
97.8 ± 1.5 % at 1 year, 91.3 ± 3.1 % at 5 years, 76.4 ± 6.1 % at 8 years, and 62.9 ± 8.7 
% at 10 years.
Table 2. Aortic valve function during follow-up in the 94 patients who survived with their 
pulmonary autograft in place
Aortic Incompetence Discharge to 3 years 4 to 6 years 7 to 9 years > 10 years
None
Trivial (grade I)
Mild (grade II)
Moderate (grade III)
Severe (grade IV)
4
11
2
1
-
13
19
8
2
-
2
12
2
1
-
5
8
4
-
-
Homograft Valve Function
None of the patients had pulmonary valve stenosis (gradient > 20 mm Hg, peak 
velocity across the pulmonary homograft > 1.4 m/s) at discharge, 9 patients (8.7%) 
had trivial pulmonary regurgitation. During follow-up, 24 patients (25.5%) developed 
pulmonary homograft stenosis. One patient, as already mentioned, underwent 
reoperation on the homograft for a stenosis of greater than 50 mm Hg. The influence 
of the variables including diameter of the pulmonary homograft, age of the donor, and 
donor status on the development of homograft stenosis was investigated. Univariate 
analysis indicated that the diameter of the pulmonary homograft (p < 0.001) was the 
only factor associated with pulmonary stenosis during follow-up. Cox proportional 
hazards regression identified smaller diameter of the pulmonary homograft and older 
age of donor as independent risk factor for the development of pulmonary homograft 
stenosis (Table 3).
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Table 3. Cox proportional hazards regression for the development of pulmonary stenosis
Characteristic Range Multivariate 
p value ª
Multivariate risk ratio per 
unit increase
(95% Confidence Limit)
Homograft Diameter (increasing)
Donor age (increasing)
20 – 30 mm
9 – 66 years old
0.001 (-)
0.002 (+)
0.6 (0.4-0.8)
1.05 (1.02-1.09)
ª The p value is followed by (-) to indicate increased risk with smaller values or (+) to indicate 
increased risk with larger values. Gradient > 20 mmHg, peak velocity across the pulmonary 
homograft > 1.4 m/s.
Functional Status
At the closure of the study, 94 patients were alive with their pulmonary autograft 
in place. Of those, 84 patients (87.2%) had no cardiac symptoms and were in 
NYHA functional class I, 11 (11.7%) were in functional class II, and 1 (1.1%) was in 
functional class III. In this patient, a recent echocardiogram revealed a severe AI 
and a pseudoaneurysm of the autograft at the distal suture line. He is scheduled for 
reoperation.
DISCUSSION
Our 11-year experience with the autograft root replacement confirms that the Ross 
procedure can be performed with low mortality and morbidity. This has only been 
possible by careful selection of the patients: only adults with few comorbidity were 
scheduled for the operation.
Autograft failure necessitating reoperation occurred in only 5 patients. In 1 patient 
the pulmonary homograft was quadricuspid and this congenital malformation was 
detected only at the end of the initial operation. The quadricuspid pulmonary valve 
is a rare congenital heart anomaly; the reported incidence ranges from 1 in 400 to 
1 in 1000 autopsies (10). The rapid progression of regurgitation of a quadricuspid 
pulmonary valve in aortic position has already been described in literature (11) and 
this graft must be considered, therefore, an inadequate candidate for use as an 
autograft in the Ross procedure.
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Aortic insufficiency during follow-up was mainly caused by dilatation at the annular 
level (1 patient) or at the sino-tubular level (2 patients). The annular dilatation can 
cause AI because it flattens the scalloped shape of the annulus, preventing coaptation 
of the cusps (12). Reinforcement of the annulus or adjustment of the diameter to 
the body surface area of the patient has been recommended for prevention of AI 
(12, 13). Therefore, in all procedures since 1997 we invariably use a reinforcement 
ring or a reduction annuloplasty if the aortic annular diameter exceeds the Z + 2 
value. In 2 patients the cause of the AI was dilatation of the pulmonary arterial wall 
at the sinotubular junction. Dilatation of the sinotubular junction cause AI because 
it pulls the commissures of the aortic valve away from the center of the aortic root, 
preventing coaptation of the cusps (12). Both patients had an bicuspid aortic valve. 
The relationship between bicuspid aortic valve and aortic wall abnormalities has 
been widely described (14, 15). Given the common embryogenesis of the aorta and 
pulmonary artery (16), Sa and colleagues (15) hypothesized that similar histologic 
lesions could exist also in the pulmonary wall of patients with bicuspid aortic valve. 
They found, in fact, a greater prevalence of degenerative changes of the media of 
the pulmonary artery of patients with an bicuspid aortic valve. We do not routinely 
reinforce the distal suture line, but are considering it.
The results of our study, in terms of autograft competence, are consistent with the 
outcomes of other studies using the autograft as a free standing root (17, 18). Over 
the last few years, the implantation technique has been addressed; in our opinion the 
free standing root technique is critical to achieve and maintain consistent autograft 
competence. There is some evidence that the long-term results, in term of valve 
competence, are superior after root replacement than after cylindric and subcoronary 
techniques (19). The advantages of the freestanding aortic root over the other two 
techniques has also been shown by Elkins and associates (13) and is probably due to 
the fact that the geometry of the autograft, and therefore the coaptation of the cusps, 
is better preserved. In contrast with this theory is the study of Sievers and associates 
(20) that shows good mid-term results with subcoronary or root inclusion technique; 
however, long-term results are needed.
The present series is of particular interest as 79.8 % of the patients with a recent 
echocardiogram have an AI less than grade 2, and continue to maintain the benefits 
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of their pulmonary autograft. The majority of them are in NYHA class I and conduct a 
normal life without anticoagulation. 
Right ventricular outflow tract reconstruction, in our series, was routinely done with a 
cryopreserved homograft. We, and others (18, 19) have noticed a significant increase 
in pulmonary flow velocities during follow-up. Pulse-wave Doppler indicated that the 
gradient was located directly at the homograft leaflets and not at the anastomosis. 
We are inclined to think, therefore, that the increased flow velocities are valve related 
and on the base of the results of the multivariate analysis, we support the current 
practice of oversizing the homograft by at least 2 to 3 mm (21); usually this results in 
a pulmonary homograft with a minimum internal diameter of 28 mm.
The influence of immune activation on human valve homograft deterioration remains 
unclear. Nevertheless, Oei and associates (22) reported that in rats, aortic valve 
homografts are able to induce a donor reactive immune response that is related 
to early graft destruction and incompetence. Further studies are needed to fully 
understand the role of immunologic factors in human valve homograft deterioration. 
Older age of donor was identified as independent risk factor for the development 
of pulmonary homograft stenosis (p = 0.002); Lund and coworkers (23) found, in a 
large series of patients, that donor age above 65 years old was a significant risk factor 
for homograft failure. According to previous studies (23, 24), however, we keep the 
donor-patient age mismatch within 10 years.
In conclusion, our long-term experience with the Ross operation has confirmed the 
suitability and safety of this operation for patients with aortic valve disease. Although 
both the aortic autograft and the pulmonary homograft have limited durability, this 
has not jet resulted in considerable reoperation rates and associated morbidity and 
mortality.
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ABSTRACT
A 37-year-old patient presented with severe aortic valve insufficiency due to massive 
dilatation of the neo-aortic root (77 mm diameter) 14 years after a Ross procedure. 
Intraoperatively, the dilatation appeared to be caused by a localized chronic dissection 
of the pulmonary autograft. Surgery consisted of a modified Bentall procedure with a 
mechanical composite valve, with an uncomplicated postoperative course.
Chronic Type A Dissection in a Pulmonary Autograft
61
4
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
INTRODUCTION
In experienced hands, the Ross operation shows minimal perioperative complications. 
Although both the autograft and the allograft have demonstrated limited durability, 
this has not yet resulted in considerable reoperation rates [1].
In the long term, however, dilatation of the pulmonary autograft root may occur [2, 3]. 
Histopathological investigations have identified the presence of cystic medial necrosis, 
elastic fragmentation and findings indicative of chronic media rupture, which may 
have been the cause of progressive dilatation [4]. Herein is reported a rare case of 
chronic type A dissection in a pulmonary autograft, identified 14 years after the initial 
Ross procedure.
Case report
In 1991, a 23-year-old man with severe insufficiency of a tricuspid aortic valve 
underwent elective aortic root replacement with the pulmonary autograft and 
implantation of a pulmonary allograft (24 mm) in the right ventricular outflow tract 
(i.e. the Ross procedure). The patient had suffered from rheumatic fever as a child. 
The postoperative period was uncomplicated, and pre-discharge echocardiography 
showed trivial neo-aortic valve insufficiency and pulmonary valve stenosis, with 
a peak pressure gradient of 18 mmHg. At two years after surgery, the aortic root 
appeared thickened on echocardiography, and the diameter had slightly dilated (38 
mm). The trivial aortic valve insufficiency persisted, and the pulmonary valve stenosis 
peak pressure gradient remained at 19 mmHg (mean 12 mmHg). In 1998, the patient 
was still symptom-free, and echocardiography revealed identical findings as described 
previously; consequently, the patient withdrew from further medical attention. In 
April 2005, the patient reported to a local hospital with acute palpitation, dyspnea 
and fatigue; he was examined but, without any conclusive diagnosis, was discharged 
with medical therapy. One month later, transthoracic echocardiography revealed a left 
ventricular end-diastolic dimension of 78 mm with massive aortic insufficiency, normal 
myocardial thickness, and contractility. The mechanism of the aortic insufficiency was 
not clear on echocardiography or subsequent angiography, though the latter technique 
showed an asymmetrically dilated proximal ascending aorta (Figure 1 A). Under the 
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suspicion of severe autograft degeneration, the patient was referred to the present 
authors’ institution. A repeat echocardiography showed severe left ventricle dilatation, 
good left ventricular function, and massive aortic insufficiency with a severe aortic 
root aneurysm (maximum diameter 77 mm). Following preoperative screening and 
acquisition of consent, the patient was reoperated on in August 2005. During surgery, 
and following redo sternotomy and extensive adhesiolysis, the asymmetrically dilated 
aortic root was evident. The right posterior side of the aortic root and ascending 
aorta was densely adherent to the superior vena cava and right atrium. Therefore, 
cardiopulmonary bypass was instituted through the groin. The distal ascending aorta 
was cross-clamped at the base of the innominate artery, and aortotomy performed. 
Myocardial arrest was achieved with antegrade Bleese cardioplegia until the septal 
temperature was 10 °C. Upon inspection of the root, there appeared to be an intimal 
rim that commenced at the lateral side of the left coronary ostium and extended 
circumferentially approximately 1 cm distal to the non-coronary annulus (Figure 1 
B). The distal anastomosis of the autograft, as well as the ascending aorta, was free 
of dissection and the aortic leaflets appeared normal. No valve-sparing procedure 
was performed as the patient had strictly requested the implantation of a mechanical 
aortic valve prosthesis. Therefore, a Bentall procedure was performed, re-implanting 
the left coronary ostium as an inlay (due to severe adhesions posteriorly) and the 
right coronary ostium as a button. The graft used as replacement was a mechanical 
composite of 29 mm diameter (Carboseal® Valsalva; CarboMedics Inc., Austin, Texas, 
USA). The patient was successfully and uneventfully weaned from extracorporeal 
circulation. 
Histologic examination of the explanted pulmonary autograft revealed degeneration 
of the elastic fibers of the media due to cystic medial necrosis (Figure 2). There was 
a sparse chronic inflammatory infiltrate in the pulmonary autograft, and no acute 
infiltrate or fibrin deposition, which confirmed chronic pulmonary autograft dissection. 
The leaflets showed normal histological findings. The hospital stay was uneventful and 
the patient discharged on day 7 after surgery. At a 16-month follow-up examination 
the patient remained asymptomatic. 
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Figure 1. (A) Aortic angiogram showing asymmetric root dilatation without a definite intimal 
flap. (B) The aortic root as viewed from the operating surgeon. An intimal rim (arrow) is present 
in the pulmonary autograft.
Figure 2. (A) Histology of the resected pulmonary autograft root wall transition, showing a 
dissection (asterisk) in the lower media of the autograft. (B) The autograft wall has a marked 
degeneration of the elastic fibers of the media due to cystic medial necrosis, with deposition 
of mucopolysaccharide material. Staining: (A) elastic van Gieson, original magnification x50; (B) 
hematoxylin and eosin, original magnification x400.
DISCUSSION
Pulmonary autograft root dilatation is one of the most common late complications 
seen after the Ross procedure [2, 3]. Likewise, it is well known that the majority of 
patients with bicuspid aortic valves have histological abnormalities in the aortic and 
the pulmonary artery wall, such as cystic medial necrosis, elastic fragmentation, and 
changes in smooth muscle cell orientation [4]. In theory, a combination of pulmonary 
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autograft dilatation and abnormal histology might lead to dissection within the 
autograft, but this long-term complication is rarely described. To the present authors’ 
knowledge, only three reports have been made regarding dissection in a dilated 
pulmonary autograft with initially a bicuspid aortic valve [5-7]. The present patient 
had a tricuspid aortic valve and had developed a chronic type A dissection in the 
dilated pulmonary autograft 14 years after the Ross procedure, with a histological 
finding of cystic medial necrosis and degeneration of the elastic fibers of the 
media. This proved that root dilatation and even dissection late after autograft root 
replacement is not only related to bicuspid aortic valve disease (which is supported by 
histopathologic studies [8, 9]), but also to other variables such as operative technique 
and hemodynamic condition, which are associated factors for root dilatation following 
the Ross procedure. 
The present case illustrates that aortic dissection may occur as a long-term complication 
in a pulmonary autograft, even with an initially tricuspid aortic valve. A high degree of 
suspicion is warranted in evaluating acute symptoms in a patient following the Ross 
procedure. Strict monitoring, for example with computed tomography, is advised to 
follow the dimensions of the autograft root. In view of the life-threatening aspect of 
this late complication, it is worth considering reoperation in an early dilated phase 
(prophylactic), as would occur in a patient with a collagen disease such as Marfan 
syndrome.
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ABSTRACT
Objective: We retrospectively evaluated our results with the valve-sparing aortic root 
replacement using the reimplantation technique.
Methods: From January 1998 through March 2010, 81 patients with a mean age of 
51.9 years (range 19 to 75 years) underwent the reimplantation technique. Indication 
for surgery was aneurysmal disease of the aorta in 65 patients (80.2 %), acute type 
A aortic dissection in 14 patients (17.3 %) and pending aortic rupture in 2 patients 
(2.5 %). 
Results: There was no hospital mortality. New neurological symptoms were observed 
in 2 patients (2.5 %) and were temporary. Mean follow-up was 65.2 months (range 
8.1 – 144.8 months). During follow-up 9 deaths occurred (11.1 %), mainly because 
of a neoplasm (n = 6). The overall survival at 1 and 5 years is 97.5 % (95 % CL, 94.2 
% - 99.9 %) and 94.4 % (95 % CL, 89.1 % - 99.9 %) respectively. No tromboembolic 
events were reported. Nine patients (11.1 %) required a reoperation due to recurrent 
severe aortic valve regurgitation (n = 7) or endocarditis of the reimplanted aortic valve 
(n = 2). Echocardiographic follow-up showed mild or no aortic valve regurgitation in 
most patients (n = 57), mild to moderate regurgitation in 5 patients and one patient 
with moderate aortic valve regurgitation. 
Conclusions: Retrospective analysis of valve-sparing aortic root replacement with 
the reimplantation technique demonstrated excellent in-hospital results, as well as 
good medium-term follow-up mortality and tromboembolic rates and an acceptable 
reoperation percentage, but close follow-up is mandatory.
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INTRODUCTION
The gold standard for patients with aortic root aneurysms is implantation of a valved 
conduit for aortic root replacement and re-implantation of the coronary buttons, first 
described by Bentall and de Bono (1). Initially these conduits contained a mechanical 
valve, but subsequently there were biological options, like the allograft and recently 
there are also biological valved conduits commercially available. These are designated 
substitutes when the aortic valve is involved in the aortic root pathology. When there 
is no valvular disease or the aortic valve regurgitation is secondary to the aortic root 
aneurysm, the morphologically normal aortic cusps can be retained. After attempts of 
repair of regurgitant aortic valves in the early years of cardiac surgery, valve-sparing 
aortic root replacement techniques for aortic valve regurgitation gained recurrent 
interest in the eighties and nineties (2-5). These procedures evolved during the years 
and are nowadays classified in a remodeling (Yacoub) and a reimplantation (David) 
technique (4,5). In our center we have used the reimplantation procedure more 
than the remodeling technique for different aortic root pathology. In this report we 
describe and analyse our experience with the reimplantation technique.
PATIENTS AND METHODS
Patients
From January 1998 through March 2010, 81 consecutive patients with a mean age of 
51.9 years (range 19 to 75 years) underwent valve-sparing aortic root replacement 
using the reimplantation technique. There were 52 male (64.2 %) and 29 female 
(35.8 %) patients. The Ethics Committee approved this retrospective cohort study 
and waived the need for patient consent. Aortic root pathology treated using the 
reimplantation technique consisted of 65 aneurysms (80.2 %), 14 acute type A aortic 
dissections (17.3 %) and 2 pending aortic ruptures (2.5 %). The intervention was a 
reoperation after previous cardiac surgery in 2 patients (2.5 %). Eighteen patients 
(22.2 %) were treated under emergent or urgent conditions, because of type A aortic 
dissection, pending aortic rupture or symptomatic, rapidly dilating aortic aneurysms. 
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One patient was preoperatively on the ventilator. Comorbid medical conditions 
consisted of hypertension (n = 47, 58.0 %), Marfan syndrome (n = 13, 16.1 %), chronic 
obstructive pulmonary disease (n = 10, 12.4 %), renal dysfunction (n = 7, 8.6 %; serum 
creatinine > 120 μmol/L, one patient on hemodialysis), previous cerebrovascular 
accident or transient ischemic attack (n = 7, 8.6 %) and diabetes (n = 5, 6.2 %). Mean 
aortic diameter for aneurysmatic disease was 59.8 ± 9.8 mm (range 44 - 90 mm). 
Concomitant aortic valve pathology consisted of severe aortic regurgitation (grade 
≥ 3) in 43 patients (53.1 %). A bicuspid aortic valve was present in 2 patients (2.5 
%). Preoperative mitral valve regurgitation (grade ≥ 3) as a comorbid cardiac lesion 
was present in 2 patients (2.5 %) and coronary artery disease in 7 patients (8.6 %). 
Pertinent patient data are given in Table 1.
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Table 1. Patient characteristics (n = 81)
No. %
Age (years)
     mean (SD ; range) 51.9 (12.4 ; 19-75)
Gender
     male 52 64.2
NYHA class
•	 I 47 58.0
•	 II 21 25.9
•	 III 5 6.2
•	 IV 8 9.9
Indication
•	 Aneurysmatic disease 65 80.3
- degenerative 34
- annuloaortic ectasia
- post-dissection
24
7
•	 Acute type A dissection 14 17.3
•	 Pending aortic rupture 2 2.5
Valvular disease
•	 Aortic valve regurgitation
- grade I 16 19.7
- grade II
- grade III
- grade IV
•	 Bicuspid aortic valve
20
23
20
2
24.7
28.4
24.7
2.5
Reoperation 2 2.5
•	 Previous mitral valve surgery
•	 Previous ascending aorta surgery
1
1
Comorbid medical conditions
     Hypertension 47 58.0
     Marfan 13 16.1
     COPD 10 12.4
     Renal insufficiency 7 8.6
     CVA 7 8.6
     Diabetes 5 6.2
SD = standard deviation; NYHA = New York Heart Association; COPD = Chronic Obstructive 
Pulmonary Disease; CVA = Cerebral Vascular Accident.
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Procedure
Standard cardiopulmonary bypass was used in all operations and carbon dioxide 
insufflation in the operation field since 2005. The aortic cannulation site was mainly 
the distal ascending aorta (n = 52) or the common femoral artery (n = 29) in case of a 
reoperation or a type A aortic dissection. Cold crystalloid antegrade cardioplegia was 
administrated through the aortic root or coronary ostia selectively with intermittent 
cardioplegic reinfusion if needed. During cardioplegic arrest, the myocardial septal 
temperature was measured and kept around 10 °C using cold saline. Depending on 
the aortic pathology, the location and extension of the lesion, a distal clamp could be 
used in 26 cases (32.1 %). If the lesion extended to the aortic arch necessitating open 
distal anastomosis, deep hypothermic circulatory arrest was used in 18 cases (22.2 
%) and antegrade selective cerebral perfusion with mild hypothermia was used in 37 
cases (45.7 %) (6, 7). The root was circumferentially dissected down to the nadir of the 
aortic annulus. All abnormal sinus tissue was excised, leaving a 5 to 6 mm rim of aortic 
tissue along the annulus. The coronary ostia were dissected in the form of a button 
and mobilized in all patients. The diameter of the aortic graft was determined using 
the David-Feindel formula: graft diameter = [2 × (Hcusp × 2/3)] + 5 mm (5). A ruler was 
used to measure the height of the cusp (Hcusp) in mm from the deepest point of the 
nadir to the free edge at the nodule of Arantius. The proximal suture technique was 
the same in all cases and consisted of suturing the proximal graft with interrupted, 
horizontal 4-0 polypropylene mattress sutures through the left ventricular outflow 
tract and continuous 5-0 polypropylene sutures in a scalloped fashion immediately 
above the insertion of the aortic cusps. Only in one patient aortic cusp repair was 
done in terms of primary closure of a fenestration.
A straight Dacron graft (Intergard, Maquet, Rastatt, Germany) was used in 46 patients 
(56.8 %) and a Valsalva graft (Gelweave Valsalva, Vascutek, Renfrewshire, Scotland) in 
35 patients (43.2 %) and the choice was based on surgeon preference. The diameter 
of the implanted straight Dacron grafts ranged from 24 to 32 mm with a median of 30 
mm and the diameter of the Valsalva grafts ranged from 26 to 30 mm with a median 
of 28 mm. Aortic root and distal ascending aorta replacement was done in 38 patients 
(46.9 %). Root replacement and ascending aorta with partial arch replacement was 
effectuated in 33 patients (40.7 %). Finally, aortic root, ascending aorta and total 
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arch replacement with or without elephant trunk was performed in 10 patients 
(12.4 %). Concomitant procedures included planned coronary artery bypass grafting 
in 7 patients (8.6 %), coronary artery bypass grafting due to peroperative technical 
problems in 1 case (1.2 %) and mitral valve repair or replacement in 2 patients (2.5 %). 
Operative data are given in detail in Table 2.
Table 2. Operative characteristics (n = 81)
No. %
Emergency
     Elective 63 77.8
     Emergent 18 22.2
 Cannulation site
     Ascending aorta
     Common femoral artery     
52
29
64.2
35.8
Perfusion data
     CPB and distal clamp
     DHCA
     ASCP
     CPB time   min, mean (SD ; range)
     Aortic clamp time
     DHCA time
     ASCP time
26
18
37
214.0 (59.9 ; 117 - 474)
152.0 (36.7 ; 66 - 230)
21.0 (5.1 ; 15 - 30)
45.0 (20.1 ; 18 - 90)
32.1
22.2
45.7
Extent of aorta replacement                 
     + Ascending 
     + Ascending and partial Arch
     + Ascending and total Arch
     + Ascending, total Arch and ET
38
33
2
8
46.9
40.7
2.5
9.9
Concomittant procedure
     CABG planned 7 8.6
     CABG unplanned 1 1.2
     Mitral valve repair or replacement 2 2.5
CPB = cardiopulmonary bypass; DHCA = deep hypothermic circulatory arrest; ASCP = antegrade 
selective cerebral perfusion; SD = standard deviation; ET = elephant trunk; CABG = coronary 
artery bypass grafting.
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Follow-up
Recent (< 6 months) information about the status of all hospital survivors was 
collected from the referring cardiologist, by visit at our outpatient clinic, our 
cardiology department or by their general physician. The closing interval for follow-up 
was between February and May 2011 and included physical examination, computed 
tomography scan, echocardiography and chest radiography, if available. End-points 
of the study were death, valve-related death, reoperation for valve failure and 
endocarditis of the aortic valve. These end-points were defined according to the 
guidelines reported by Akins and associates (8).
Data Analysis
Retrospective review was done on the data of all consecutive patients who 
underwent valve-sparing aortic root replacement using the reimplantation technique. 
Quantitative data are presented as mean ± standard deviation. Odds Ratio’s (OR) and 
Fisher’s exact p-value were used for comparison. Kaplan-Meier survival curves were 
used for analysis of survival times. Precision was indicated by 95 % confidence limits 
(CL). All statistical analyses were done by R (version 2.9 www.r-project.org).
RESULTS
Early Results
There were no hospital deaths. Median intensive care unit stay was 3 days (range 
1 – 52 days). Six patients (7.4 %) needed ventilatory support for > 48 hours and a 
tracheostomy was inserted in 2 patients (2.5 %). A rethoracotomy was performed in 
14 patients (17.3 %), mostly for excessive bleeding (n = 8), because of leakage from the 
coronary reattachment line (n = 3), from the distal suture line (n = 3) or cannulation 
site (n = 2). Clinical signs of tamponade (n = 6) were also a predominant reason for 
rethoracotomy. There was no permanent pacemaker implantation. Postoperative 
temporary hemodialysis was necessary in 2 patients (2.5 %) and both recovered 
without need for long-term dialysis. 
New neurological symptoms were observed in 2 emergently operated patients (2.5 %) 
after a type A dissection. Ischemic cerebral accident occurred in 1 patient and critical 
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illness polyneuropathy in 1 patient. The neurological symptoms were all temporary 
and resolved completely.
Follow-up results
All hospital survivors (n = 81) were entered in the follow-up study (100 % complete). 
Mean follow-up was 65.2 months (range 8.1 – 144.8 months). Total follow-up was 440 
patient-years. During follow-up 9 patients (11.1 %) died. Cause of death during follow-
up was neoplasm in 6 patients, cardiac failure in 1 patient and unknown in 2 patients. 
The mean period between initial valve-sparing aortic root replacement and death was 
53.1 months (range 2.1 – 114.6 months). The last echocardiography available before 
death showed predominantly a mild aortic valve regurgitation (grade I/IV n = 7) and 
two patients had mild to moderate aortic valve regurgitation (grade II/IV n = 2). The 
overall survival at 1 and 5 years is 97.5 % (95 % CL, 94.2 % - 99.9 %) and 94.4 % (95 % 
CL, 89.1 % - 99.9 %) respectively. This is presented in Figure 1.
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Figure 1. Kaplan-Meier survival curve after valve-sparing aortic root replacement with the 
reimplantation technique.
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Seven patients (8.6 %) required a reoperation for recurrence of severe aortic valve 
regurgitation en two patients (2.5 %) underwent a reoperation, because of endocarditis 
of the spared aortic valve. These reoperated patients had an aortic regurgitation at 
discharge of trivial to mild (grade ≤ I/IV) on echocardiography. Mean period between 
the initial reimplantation procedure and reoperation was 43.3 months (range 20.5 
– 102.8 months). One patient received a homograft and the rest of the patients an 
aortic valve replacement with a mechanical valve. None of the patients died after a 
reoperation. Two other patients underwent descending aorta replacement, because 
of an aneurysm. The 1 and 5 years freedom from reoperation is 100 % (95 % CL, 96.0 
% - 100 %) and 86.8 % (95 % CL, 78.7 % - 95.8 %) respectively. This is presented in 
Figure 2.
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Figure 2. Freedom from reoperation curve after valve-sparing aortic root replacement with the 
reimplantation technique.
Valve-sparing Aortic Root Replacement using the Reimplantation Technique: Single Center Experience
77
5
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
New onset endocarditis of the reimplanted aortic valve was reported in 2 patients 
(2.5 %) and both were reoperated as described above and survived. Both patients 
had Streptococcus as a cultured microorganism. No late tromboembolic or bleeding 
events were reported and also no false aneurysms were seen.
Follow-up imaging was done by echocardiography. This showed severe aortic valve 
regurgitation in 7 patients en endocarditis in 2 patients, who were reoperated as 
described above. Beside these patients the majority of the follow-up patients had 
mild aortic valve regurgitation (grade I/IV n = 57), 5 patients had mild to moderate 
aortic valve regurgitation (grade I-II/IV) and in one patient moderate aortic valve 
regurgitation (grade II/IV) was observed. The last patient had no symptoms and is 
being followed up. 
DISCUSSION
Aortic regurgitation can be the result of disease from the aortic valve, the ascending 
aorta or both. When there is no valvular disease or the aortic valve regurgitation is 
secondary to the aortic root pathology (aneurysm), the morphologically normal 
aortic cusps can be retained. In our institution the reimplantation technique for valve-
sparing aortic root replacement, first described by David and Feindel in 1992, is most 
commonly used (5). After reports with promising mid-term results in 1997 we started to 
use the aortic valve reimplantation technique (9, 10). Initially, aortic root or ascending 
aorta aneurysms were the primary indication for this reimplantation technique. After 
gaining more experience the indication expanded to type A dissections if the aortic 
valves were unaffected. 
In this retrospective analysis of 81 patients with a mean age of 51.9 years, with 
predominantly an aneurysm or a type A dissection, who underwent valve-sparing 
aortic root replacement with the reimplantation technique, there was no hospital 
mortality. There were 2 major adverse events in terms of ischemic cerebral accident 
in 1 patient and critical illness polyneuropathy in another patient. Both patients were 
emergently operated after a type A dissection. These new neurological symptoms 
were temporary and resolved completely. These short-term results are excellent and 
similar to other reports about the reimplantation technique (11-14). 
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During a mean follow-up of 65.2 months 9 patients (11.1 %) died, mainly because of 
a neoplasm (n = 6). These patients had predominantly mild aortic valve regurgitation 
before death. The overall survival at 5 years is 94.4 % (95 % CL, 89.1 % - 99.9 %), 
which is comparable with other reports on the reimplantation technique (11-14). The 
5 years survival of our mechanical Bentall group (mean age 54 years) is 87 % (15). A 
direct comparison between these groups would not be correct, because the patient 
groups are not comparable.
Reoperation for recurrence of severe aortic valve regurgitation was necessary for 7 
patients (8.6 %) after a mean period of 43.3 months between the initial reimplantation 
procedure and reoperation. Half of the patients (n = 4) who needed a reoperation were 
initially operated in the ‘learning curve’ phase at the beginning of the reimplantation 
technique in our institution. Five reoperated patients had a straight Dacron graft and 
2 patients a Valsalva graft, but univariate analysis showed no significance between 
the type of graft and reoperation (HazardRatio = 0.88, 95 % CL, 0.21 - 3.69, p = 0.86). 
Only one reoperated patient was a Marfan patient. There were 2 other patients who 
were reoperated because of endocarditis of the reimplanted aortic valves. The 5 years 
freedom from reoperation is 86.8 % (95 % CL, 78.7 % - 95.8 %). Compared to other 
reimplantation technique reports our reoperation percentage (11.1 %) is acceptable 
(12-14). Only the group of David and associates has an excellent rate of reoperation 
of the reimplantation procedure of 0.9 % (2/228) (11). The risk of a reoperation in 
the future for recurrence of aortic regurgitation should be weight preoperatively 
together with the patient to the risk of anticoagulation related complications, when 
a mechanical conduit is used or even if a biological valved conduit is chosen (16). 
Nowadays, some biological valved conduits have good clinical results and these 
should be considered in elderly ( > 70 years) patients instead of valve-sparing aortic 
root replacement, which is surgically more demanding with longer aortic cross clamp 
times and the chance to be reoperated in the future (17). 
In our institution, after valve-sparing aortic root replacement, patients get only the 
first 3 months acetyl salicylic acid. Thereafter, anticoagulation is stopped, unless there 
is another indication. During the follow-up of 440 patient-years no thromboembolic or 
bleeding events were reported. In this view the valve-sparing aortic root replacement 
with the reimplantation technique is superior to mechanical and biological valved 
conduits (15-17).
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In conclusion, our results of valve-sparing aortic root replacement with the 
reimplantation technique show excellent in-hospital morbidity and mortality rates 
as well as good medium-term follow-up mortality and tromboembolic rates. The 
reoperation percentage for recurrent aortic regurgitation is acceptable, but close 
follow-up is mandatory and long term results are to be awaited for.
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ABSTRACT
We present a case of a traumatic aorto-right ventricular fistula coexistent with 
aortic insufficiency due to perforation of the left coronary leaflet, which is a lesion 
rarely described in the literature. We compare our experience with reports from the 
literature.
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INTRODUCTION
Since the first case report of traumatic aorto-right ventricular fistula in 1958, there 
have been 42 case reports in literature [1-3]. Only 17 of these describe the combination 
of traumatic aorto-right ventricular fistula with aortic insufficiency [2, 3]. We present 
a case of an aorta to the right ventricular fistula combined with aortic insufficiency 
after a penetrating trauma. The aim is to compare our experience with the various 
approaches described in the literature. 
Case report
A 19-year-old man was stabbed with a small bladed stiletto knife in the left third 
intercostal space adjacent to the sternum. On admission, the patient was alert 
and responsive with stable vital signs. There was no significant past medical 
history or medication. There was no thrill or murmur heard on examination. Chest 
roentgenogram showed fluid in the left hemithorax. A mild to moderate amount 
of pericardial effusion associated with left sided-pleural fluid was detected by 
transthoracic echocardiography. Mild aortic valve insufficiency and a small ventricular 
septal defect was also seen (Fig 1). Unfortunately the patient refused transesophageal 
echocardiography, which could give more detailed information about the pathology. A 
left-sided chest drain produced 1270 ml of serosanguineous fluid over a 2-day period. 
At re-evaluation by transthoracic echocardiography the findings were unchanged. The 
patient was hemodynamically stable and maintained adequate oxygen saturation. He 
had no complaints and was optimally mobilized. He made an uneventful recovery and 
insisted on being discharged against medical advice. He did not report for follow-up at 
the outpatient clinic. A month later he was urgently readmitted due to severe dyspnea. 
A continuous pre-cordial murmur was heard on auscultation and congestion of his 
jugular veins was evident. Pericardial tamponade was confirmed by transthoracic 
echocardiography and subxiphoid pericardiocentesis was performed with 1060 ml 
of blood evacuated. Re-evaluation with transthoracic echocardiography confirmed 
moderate aortic valve regurgitation, an increased left to right shunt between the 
aortic root and right ventricular outflow tract, and a moderately dilated right ventricle 
(Fig 1). 
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Figure 1. Parasternal short axis view showing increased left to right shunt (arrow) after 1 month. 
(Ao = Aorta; RA = Right Atrium; RV = Right Ventricle; RVOT = Right Ventricular Outflow Tract)
At surgery, a median sternotomy was performed, the pericardium was opened, and the 
epicardial adhesions were released. On cardiopulmonary bypass with double venous 
cannulation, cold crystalloid cardioplegia was selectively infused through the coronary 
ostia untill a septal temperature of 10 °C was achieved. The aorto-right ventricular 
communication was exposed through the transverse aortotomy. An imaginary line 
could be drawn from the lacerated left coronary cusp, crossing the interleaflet triangle 
between the left and right coronary cusp, penetrating the right ventricular outflow 
tract (Fig 2). A small opening was also noticed in the pericardium covering the right 
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ventricle, thus confirming the trajectory of the penetrating injury. No superficial entry 
wound was found on the right ventricle, probably due to the adhesions. The septal 
communication was closed through the aortotomy with continuous 5-0 polypropylene 
suture. A small (5 mm) clean cut longitudinal laceration at the base of the left coronary 
cusp of the aortic valve could be repaired primarily with a double layer continuous 
7-0 polypropylene suture (Fig 2). Postoperatively to the repair, an intraoperative 
transesophageal echocardiographic evaluation showed no evidence of aortic valve 
insufficiency or left to right shunt. The postoperative course was uneventful and the 
patient was discharged on postoperative day 5. To our disappointment, thus far the 
patient has continued to abstain from following up at the outpatient clinic.
Figure 2. Artist impression of an intracardiac direction of penetrating injury (arrow). Inset: 
postoperative repair diagram of left coronary cusp (asterisk). (LCC = Left Coronary Cusp; LCO = 
Left Coronary Ostium; RVOT = Right Ventricular Outflow Tract.)
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DISCUSSION
Traumatic aorto-right ventricular fistulas with aortic insufficiency are rare lesions after 
penetrating thoracic injuries. According to the literature this specific lesion has been 
reported 17 times previously [2, 3]. 
The time interval between injury and surgical intervention is variable. Some patients 
require immediate surgical management due to instable hemodynamics, but others 
may have a delayed clinical presentation and therefore delayed repair [3-5]. The 
interval until definitive repair could be as long as 17 years, as reported by Ehrenstein 
and colleagues [6]. In this case, the time interval between injury and repair was 56 
days. The propensity for shunts in aorto-right ventricular fistulas to increase in size 
with time may explain the delayed time interval to definitive repair as reported by 
some authors [3-5, 7]. All patients with a traumatic aorta to right ventricular fistula 
combined with aortic insufficiency (except for one patient) were operated on sooner 
or later, as reported in the review by Samuels and colleagues [2]. Our experience 
confirms that a traumatic aorto-right ventricular shunt with aortic insufficiency has a 
tendency to increase in size with time. Therefore it is advisable that these patients be 
operated on at an early stage.
Although patients with aorto-right ventricular fistula combined with aortic insufficiency 
after a penetrating trauma may have no cardiac symptoms, they should be thoroughly 
evaluated, preferably by transesophageal echocardiography and operated on during 
the same admission. If left untreated, congestive heart failure will invariably develop.
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ABSTRACT
Objectives: We retrospectively evaluated our results with the Shelhigh biological 
conduit model NR-2000C (Shelhigh, Inc, Millburn, NJ).
Methods: From November 1998 through December 2007, 175 patients with a mean 
age of 71.1 ± 7.4 years underwent aortic root replacement with a Shelhigh biological 
conduit. Indication for surgery was aneurysmal disease of the aorta in 120 (68.6 %) 
patients, aortic valve endocarditis in 20 (11.4 %), acute type A aortic dissection in 11 
(6.3 %), and other in 24 (13.7 %) patients.
Results: Overall hospital mortality was 13.7 % (n=24; 95% confidence limits, 9.0 
% - 19.7 %). Cause of death was cardiac failure in 12 patients, central neurological 
damage in 5 patients, pulmonary in 3 patients, gastrointestinal ischemia in 2 patients, 
and aorta-related in 2 patients. Mean follow-up was 3.1 years (range 0.2 - 9.9 years). 
In total, 50 (33.1%) late deaths occurred; of these 7 were valve-related. The overall 
survival at 1 and 5 years is 77.6 % ± 3.2 % and 54.6 % ± 4.6 % respectively. Six (4.0 
%) patients required reoperation, either for endocarditis of the bioconduit (n=5) or 
for false aneurysm (n=1). Endocarditis of the bioconduit was reported in 11 (7.3 %) 
patients, of whom 6 were treated nonoperatively and 5 required reoperation.
Conclusions: Midterm results of the implantation of the Shelhigh biological valved 
conduit are worrisome. The relatively high incidence of endocarditis of the Shelhigh 
bioconduit has forced us to look for other alternatives.
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INTRODUCTION
Bentall and DeBono described the first complete replacement of the aortic root with 
a conduit in 1968 (1). The initial composite valved graft contained a mechanical valve, 
but nowadays there are also complete biological conduits as substitute for aortic root 
replacement. The homograft or autograft is an alternative but has the disadvantage 
of limited donor availability and durability (2). Aortic valve-sparing surgery may not be 
applicable for all pathologic situations of the aortic root and in particular the aortic 
valve (3, 4). Nowadays, only a few biological valved conduits are readily available off 
the shelf in all sizes and without the need for lifelong oral anticoagulation. At the end 
of the nineties, a new stentless biological valved conduit, Shelhigh bioconduit, model 
NR-2000C (Shelhigh, Inc, Millburn, NJ), was introduced. This is a bovine pericardial 
straight graft with an incorporated porcine stentless valve, which is glutaraldehyde 
cross-linked, detoxified, and heparin-treated (No-React process). Since 1998 we have 
used this biological valved conduit for aortic root replacement in the elderly patients 
or for specific indication, such as infective aortic root abscesses. In this report we 
describe and analyse our initial results.
PATIENTS AND METHODS
Patients
From November 1998 through December 2007, 175 patients with a mean age of 
71.1 years (range 31-84 years) underwent aortic root replacement with a Shelhigh 
bioconduit model NR-2000C. Fifty-two (29.7 %) patients were 75 years or older. 
There were 102 (58.3%) male and 73 (41.7%) female patients. The Ethics Committee 
approved this retrospective cohort study and waived the need for patient consent. 
Aortic root diseases treated with this complete biological conduit consisted of the 
following: aneurysm, n = 120 (68.6 %); aortic valve endocarditis, n = 20 (11.4 %); acute 
type A aortic dissection, n = 11 (6.3 %), calcified (‘porcelain’) aortic root, n = 8 (4.6 
%); and other, for example, small aortic annulus or aortic stenosis owing to pannus 
formation after previous aortic valve replacement, n = 16 (9.1 %). The intervention 
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was a reoperation after previous cardiac surgery in 45 patients (25.7 %) of whom the 
majority (33 patients) had previous aortic valve surgery. Twenty-two (12.6 %) patients 
were treated under emergency conditions. Four (2.3 %) patients were preoperatively 
supported with the ventilator, mainly owing to complicated type A aortic dissection or 
prosthetic valve endocarditis. Comorbid medical conditions consisted of hypertension 
(n = 123, 70.3 %), renal dysfunction (n = 25, 14.3 %; serum creatinine > 120 μmol/L 
among whom 2 required hemodialysis), chronic obstructive pulmonary disease (n = 
23, 13.1 %), previous cerebrovascular accident or transient ischemic attack (n = 16, 9.1 
%), diabetes (n = 13, 7.4 %) and Marfan syndrome (n = 3, 1.7 %). Mean aortic diameter 
for aneurysmatic disease was 59.7 ± 10.1 mm (range 43-108 mm). Concomitant aortic 
valve disease consisted of severe aortic regurgitation (grade ≥ 3) in 88 patients (50.3 
%), moderate to severe aortic valve stenosis (mean gradient 65.6 ± 25.6 mmHg) in 
54 patients (30.9 %) and mixed aortic valve lesion in 26 patients (14.9 %). A bicuspid 
aortic valve was present in 16 patients (9.1 %). Preoperative mitral valve regurgitation 
(grade ≥ 3) as a comorbid cardiac lesion was present in 8 patients (4.6 %) and coronary 
artery disease in 46 patients (26.3 %). Pertinent patient data are given in Table 1.
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Table 1. Patient characteristics (n=175)
No. %
Age (years)
     mean (SD ; range) 71.1 (7.4 ; 31-84)
Gender
     male 102 58.3
NYHA class
•	 I 30 17.1
•	 II 62 35.5
•	 III 53 30.3
•	 IV 30 17.1
Indication
•	 Aneurysmatic disease 120 68.6
- degenerative 110
- false 6
- post dissection 4
•	 Aortic valve endocarditis 20 11.4
- prosthetic 16
- native 4
•	 Acute type A dissection 11 6.3
•	 Calcified aortic root 8 4.6
•	 Other
Valvular disease
•	 Aortic valve regurgitation
- grade I
16
55
9.3
31.4
- grade II
- grade III
- grade IV
•	 Aortic valve stenosis
  mean gradient, mmHg (SD;range)
•	 Mixed aortic valve lesion
•	 Bicuspid aortic valve
32
55
33
54
65.6 (25.6 ; 20-135)
26
16
18.3
31.4
18.9
30.9
14.9
9.1
Reoperation 45 25.7
•	 Previous aortic valve surgery 33
Comorbid medical conditions
     Hypertension 123 70.3
     Renal insufficiency 25 14.3
     COPD 23 13.1
     CVA 21 12.0
     Diabetes 13 7.4
     Marfan 3 1.7
SD = standard deviation; NYHA = New York Heart Association; COPD = Chronic Obstructive 
Pulmonary Disease; CVA = Cerebral Vascular Accident.
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Procedure
Full aortic root replacement for composite valve graft insertion with the button 
technique for reattachment of the coronary ostia was used in all patients in combination 
with standard cardiopulmonary bypass (5). The aortic cannulation site was mainly the 
distal ascending aorta or the common femoral artery in case of a reoperation or a 
type A dissection. Cold crystalloid cardioplegic solution was administrated antegradely 
through the aortic root or coronary ostia selectively with intermittent cardioplegic 
reinfusion if needed. During cardioplegic arrest, the myocardial septal temperature 
was measured and kept around 10 °C using a Shumway cold line. Depending on the 
aortic disease, the location and extension of the lesion, a distal clamp could be used in 
67 (38.3 %) patients. If the lesion extended to the aortic arch necessitating open distal 
anastomosis, deep hypothermic circulatory arrest was used in 63 (36.0 %) patients 
and antegrade selective cerebral perfusion with mild hypothermia was used in 45 
(25.7 %). The latter technique was used when a circulatory arrest period of more than 
30 minutes was anticipated (6, 7). The proximal suture technique was by preference of 
the surgeon and consisted of three separate, continuous 4-0 polypropylene sutures (n 
= 108, 61.7%) for the attachment of the bioconduit sewing ring to the aortic annulus 
or interrupted pledget-supported 2-0 braided polyester mattress sutures (n = 67, 38.3 
%). In recent years a continuous 5-0 polypropylene suture was used to reinforce the 
proximal annular anastomosis against anastomotic leakage. 
The diameter of the implanted biological conduits ranged from 21 to 27 mm with a 
median of 25 mm. Aortic root replacement solely was done in only 12 patients (6.9 %). 
Aortic root and distal ascending aorta replacement was realized in 72 patients (41.1 
%). Root replacement and ascending aorta with partial arch replacement was effected 
in 68 patients (38.9 %). Finally, aortic root, ascending aorta and total arch replacement 
with or without elephant trunk was performed in 23 patients (13.1 %). In 99 patients 
(56.6 %) a woven vascular graft was used as an extension of the bioconduit and the 
native downstream aorta. The graft diameter ranged from 22 to 32 mm with a median 
of 26 mm.
Concomitant procedures included planned coronary artery bypass grafting in 41 
patients (23.4 %), coronary artery bypass grafting owing to peroperative technical 
problems in 6 patients (3.4 %), mitral valve repair or replacement in 5 patients (2.9 %), 
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combination of planned coronary artery bypass grafting and mitral or tricuspid valve 
surgery in 5 patients (2.9 %) or other procedures in 7 patients (4.0 %), like Morrow 
procedure or closure of an atrial septal defect. Operative data are given in detail in 
Table 2.
Table 2. Operative characteristics (n=175)
No. %
Emergency
     Elective 153 87.4
     Emergent 22 12.6
 Cannulation site
     Ascending aorta
     Common femoral artery
     Axillary artery
134
39
2
76.6
22.3
1.1
Perfusion data
     CPB and distal clamp
     DHCA
     ASCP
     CPB time; min, mean (SD ; range)
     Aortic clamp time
     DHCA time
     ASCP time
67
63
45
190.4 (53.6 ; 117 - 376)
125.1 (30.2 ; 73 - 228)
24.5 (5.9 ; 17 - 40)
57.1 (14.8 ; 38 - 79)
38.3
36.0
25.7
Conduit suture technique
     Continuous polypropylene sutures
     Interrupted pledgeted polyester sutures
108
67
61.7
38.3
Extent of aorta replacement
     Root only
     + Ascending 
     + Ascending and partial Arch
     + Ascending and total Arch
     + Ascending, total Arch and ET
12
72
68
6
17
6.9
41.1
38.9
3.4
9.7
Concomittant procedure
     CABG planned 41 23.4
     CABG unplanned 6 3.4
     Mitral valve repair or replacement 5 2.9
     Combination 5 2.9
     Other 7 4.0
CPB = cardiopulmonary bypass; DHCA = deep hypothermic circulatory arrest; ASCP = antegrade 
selective cerebral perfusion; SD = standard deviation; ET = elephant trunk; CABG = coronary 
artery bypass grafting.
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Follow-up
Recent (< 6 months) information about the status of all hospital survivors was 
collected from the referring cardiologist, by visit at our outpatient clinic, our 
cardiology department, or by their general physician. December 31, 2008 was the 
closing date for follow-up and included physical examination, computed tomography 
scan, echocardiography, and chest radiography, if available. Endpoints of the study 
were death, valve-related death, reoperation for valve failure, and endocarditis of the 
bioconduit. These endpoints were defined according to the guidelines reported by 
Akins and associates (8).
Data Analysis
Retrospective review was done on the data of all consecutive patients who underwent 
aortic root replacement with the Shelhigh bioconduit. Quantitative data are presented 
as mean ± standard deviation. Odds Ratio’s (OR) and Fisher’s exact p value were used 
for comparison. Kaplan-Meier survival curves were used for analysis of survival times. 
Precision was indicated by 95 % confidence limits (CL). All statistical analyses were 
done by R (version 2.9 www.r-project.org).
RESULTS
Early Results
Overall hospital mortality was 13.7 % (n = 24; 95 % CL, 9.0 % - 19.7%), of which 8.5 % was 
for elective and 50.0 % for emergency cases (p < 0.0001). All the patients undergoing 
emergency surgery who died had acute type A dissection or endocarditis, and the 
predominant cause of death were ischemic cardiac or severe neurological causes. 
There were 3 intraoperative deaths (1.7 %). All patients who died intraoperatively 
had poor left ventricular function (ejection fraction ≤ 25 %), 2 had emergency 
operations and the causes of death were cardiac failure, myocardial infarction, and 
electromechanical dissociation after ventricular fibrillation. Causes of in-hospital 
death are summarized in Table 3. Univariate analysis showed acute type A dissection 
(OR 9.7; 95 % CL, 2.7 - 35.2; p = 0.0005), endocarditis (OR 4.4; 95 % CL, 2.5 – 7.7; 
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p = 0.0058) and emergency operation (OR 10.8; 95 % CL, 6.4 – 18.1; p < 0.0001) as 
important variables for hospital mortality. Multivariate analysis did not produce any 
independent predictor. Especially, there was no independent association between 
indication type and emergency operation on hospital mortality. The hospital mortality 
for patients with an aortic aneurysm (non-dissection and non-endocarditis) having 
elective surgery was 4.2 % (n = 5). In 6 patients (3.4 %), intra-operative problems 
required a second cardiopulmonary bypass run and in 5 of these patients a second 
crossclamp of the aorta with cardioplegic arrest was necessary. Main cause was 
to obtain control of bleeding from the proximal suture line or left coronary ostium 
anastomosis.
Mean and median intensive care unit stay was 6 days and 3 days respectively (range 
1 – 60 days). Thirty-one patients (18.0 %) needed ventilatory support for more than 
48 hours and a tracheostomy was inserted in 9 patients (5.2 %). A rethoracotomy was 
performed in 48 patients (27.9 %), mostly for excessive bleeding (n = 18), because of 
diffuse leakage (n = 8), from the coronary reattachment line (n = 4), distal bioconduit 
suture line (n = 2), proximal bioconduit suture line (n = 2) or other (n = 2). Signs of 
tamponade (n = 17) were also a predominant reason for rethoracotomy and only 
half of these patients (n =9) did have a clear tamponade during the rethoracotomy. 
A planned rethoracotomy in the next few days for removal of gauzes (n =12) was 
the third major cause of rethoracotomy. Perioperative myocardial damage (serum 
creatinine kinase level > 300 IU/L, with a creatinine kinase MB isoenzyme fraction > 5 
%) occurred in 14 patients (8.1 %). Permanent pacemaker implantation was necessary 
in 17 patients (9.9 %). Postoperative temporary hemodialysis was necessary in 7 
patients (4.1 %). Three of these patients died in the hospital, the others recovered 
without the need for long-term dialysis. 
New neurological symptoms were observed in 23 patients (13.1 %). Ischemic cerebral 
accidents occurred in 19 patients, critical illness polyneuropathy in 2 patients and 
transient peripheral neuropathy in 2 patients. In the stroke group 7 patients died 
in the hospital, 2 of non-neurological causes, and permanent neurological damage 
was manifest in 6 patients (3.4 %). The odds radio for ischemic stroke in the group 
having deep hypothermic circulatory arrest was 4.6 (95 % CL, 1.7 – 12.8, p = 0.0035) 
in comparison with the group having antegrade selective cerebral perfusion and distal 
clamping.
Chapter 7 
98
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
Table 3. Causes of Early and Late death (n=74)
Causes of death No. %
Early : In hospital 24 13.7
     Operative
- Elective    :    -arrhythmia
- Emergent :     -heart failure
                           -ischemic 
3
          1          
          1
          1
1.7
     Postoperative, hospital 
       - Elective : 
                         - cardiac
 - cerebrovascular accident
 - respiratory failure
 - bleeding (proximal anastomosis)
       - Emergency :  
                            - cardiac
    - cerebrovascular accident
    - respiratory failure
    - gastro-intestinal ischemia
21
          
14
          6
          3
          3
          2
7
         2
         2
         1
         2
12.0
Late : Follow-up 50 33.1
     Prosthesis related
endocarditis
               - early (< 1 year)
               - late (> 1 year)
7
          7
          4
          3
4.6
     Cardiac 
- ischemic
- heart failure
- arrhythmia
- endocarditis MV prosthesis
8
          4        
          2
          1
          1
5.3
     Neurological 
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Late results
There were 151 hospital survivors and all were entered in the follow-up study (100 
% complete). Mean and median follow-up was 3.1 years and 2.9 years respectively 
(range 0.2-9.9 years). Total follow-up was 543 patient-years. During follow-up, 50 
(33.1 %) patients died, and 15 of these deaths occurred in the first postoperative 
year. Causes of death during follow-up are summarized in Table 3. Seven of these late 
deaths were prosthesis-related owing to endocarditis of the bioconduit. Among the 
other 43 patients with non-prosthesis related late deaths, 8 patients died of cardiac 
causes, 1 of whom had recurrent endocarditis of the mitral valve prosthesis (Shelhigh) 
with vegetations on echocardiography. The overall survival at 1 and 5 years is 77.6 
% ± 3.2 % and 54.6 % ± 4.6 % respectively. This information is presented in Figure 
1 for the total group and selectively for the patients having elective and emergency 
operations. For the complete follow-up period, there is a significant difference 
between the elective and emergency groups (p = 0.003). After exclusion of the first 30 
postoperative days, this difference disappears (p = 0.679).
were also a predominant reason for rethoracotomy, and only
half of these patients (n¼ 9) did have a clear tamponade dur-
ing the rethoracotomy. A planned rethoracotomy in the next
few days for removal of gauzes (n¼ 12) was the third major
cause of rethoracotomy. Perioperative myocardial damage
(serum creatinine kinase level>300 IU/L, with a creatinine
kinaseMB isoenzyme fraction>5%) occurred in 14 (8.1%)
patients. Permanent pacemaker implantation was necessary
in 17 (9.9%) patients. Postoperative temporary hemodialy-
sis was necessary in 7 (4.1%) patients. Three of these pa-
tients died in the hospital, the others recovered without the
need for long-term dialysis.
New neurologic symptoms were observed in 23 (13.1%)
patients. Ischemic cerebral accidents occurred in 19 patients,
critical illness polyneuropathy in 2 patients, and transient
peripheral neuropathy in 2 patients. In the stroke group, 7 pa-
tients died in the hospital, 2 of nonneurologic causes, and
permanent neurologic damage was manifest in 6 (3.4%)
patients. The OR for ischemic stroke in the group having
deep hypothermic circulatory arrest was 4.6 (95% CL,
1.7–12.8; P ¼ .0035) in comparison with the group having
antegrade selective cerebral perfusion and distal clamping.
Late Results
There were 151 hospital survivors and all were entered in
the follow-up study (100% complete). Mean and median
follow-up were 3.1 years and 2.9 years, respectively (range
0.2–9.9 years). Total follow-up was 543 patient-years. Dur-
ing follow-up, 50 (33.1%) patients died, and 15 of these
deaths occurred in the first postoperative year. Causes of
death during follow-up are summarized in Table 3. Seven
of these late deaths were prosthesis related owing to endo-
carditis of the BioConduit. Among the other 43 patients
with non–prosthesis-related late deaths, 8 patients died of
cardiac causes, 1 of whom had recurrent endocarditis of
the mitral valve prosthesis (Shelhigh), with vegetations on
echocardiography. The overall survivals at 1 and 5 years
are 77.6% � 3.2% and 54.6% � 4.6%, respectively.
This information is presented in Figure 1 for the total group
and selectively for the patients having elective and emer-
gency operations. For the complete follow-up period, there
is a significant difference between the elective and emer-
gency groups (P¼ .003). After exclusion of the first 30 post-
operative days, this difference disappears (P ¼ .679).
Six (4.0%) patients required reoperation for significant
prosthesis dysfunction owing to endocarditis of the BioCon-
duit (n¼ 5) and false aneurysm (n¼ 1). Mean length of time
between the initial aortic root replacement and reoperation
was 21.7 months � 22.1 months. Three patients underwent
reoperation within 1 year after the initial root replacement,
and in all these cases the cause of reoperation was endocar-
ditis. During reoperation most patients received a second
Shelhigh BioConduit, except 1 patient who received a homo-
graft. One patient, known to have a false aneurysm, is being
followed up conservatively because she underwent multiple
sternal wound explorations, and a reoperation for false aneu-
rysm correction is estimated to be too high a risk. One patient
died after reoperation for endocarditis. One- and 5-year free-
dom from reoperation is 76.4%� 3.2% and 50.8� 4.6% as
presented in Figure 2.
Endocarditis of the Shelhigh BioConduit was reported in
11 (7.3%) patients. Five of these patients were reoperated on
and only 1 patient died 3 months after the reoperation, as de-
scribed earlier. Six patients were not referred for surgery by
their cardiologist and were treated medically, and all these
patients died subsequently. Two of them had autopsy, which
FIGURE 1. Survival curve after aortic root replacement with a Shelhigh
BioConduit for the elective, emergency, and total group.
FIGURE 2. Freedom from reoperation after aortic root replacement with
a Shelhigh BioConduit.
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Figure 1. Survival cur e afte  aortic oot replacem nt with a Shelhigh bioconduit for the elective, 
emergency and total group.
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Six (4.0 %) patients required reoperation for significant prosthesis dysfunction owing 
to endocarditis of the bioconduit (n = 5) and false aneurysm (n = 1). Mean length of 
time between the initial aortic root replacement and reoperation was 21.7 months ± 
22.1 months. Three patients underwent reoperation within one year after the initial 
root replacement, and in all these cases the cause of reoperation was endocarditis. 
During reoperation most patients received a second Shelhigh bioconduit, except one 
patient who received a homograft. One patient, known to have a false aneurysm, is 
being followed up conservatively because she underwent multiple sternal wound 
explorations, and a reoperation for false aneurysm correction is estimated to be a 
too high risk. One patient died after reoperation for endocarditis. One- and five-year 
freedom from reoperation is 76.4 % ± 3.2 % and 50.8 ± 4.6 % as presented in Figure 2.
were also a predominant reason for rethoracotomy, and only
half of these patients (n¼ 9) did have a clear tamponade dur-
ing the rethoracotomy. A planned rethoracotomy in the next
few days for removal of gauzes (n¼ 12) was the third major
cause of rethoracotomy. Perioperative myocardial damage
(serum creatinine kinase level>300 IU/L, with a creatinine
kinaseMB isoenzyme fraction>5%) occurred in 14 (8.1%)
patients. Permanent pacemaker implantation was necessary
in 17 (9.9%) patients. Postoperative temporary hemodialy-
sis was necessary in 7 (4.1%) patients. Three of these pa-
tients died in the hospital, the others recovered without the
need for long-term dialysis.
New neurologic symptoms were observed in 23 (13.1%)
patients. Ischemic cerebral accidents occurred in 19 patients,
critical illness polyneuropathy in 2 patients, and transient
peripheral neuropathy in 2 patients. In the stroke group, 7 pa-
tients died in the hospital, 2 of nonneurologic causes, and
permanent neurologic damage was manifest in 6 (3.4%)
patients. The OR for ischemic stroke in the group having
deep hypothermic circulatory arrest was 4.6 (95% CL,
1.7–12.8; P ¼ .0035) in comparison with the group having
antegrade selective cerebral perfusion and distal clamping.
Late Results
There were 151 hospital survivors and all were entered in
the follow-up study (100% complete). Mean and median
follow-up were 3.1 years and 2.9 years, respectively (range
0.2–9.9 years). Total follow-up was 543 patient-years. Dur-
ing follow-up, 50 (33.1%) patients died, and 15 of these
deaths occurred in the first postoperative year. Causes of
death during follow-up are summarized in Table 3. Seven
of these late deaths were prosthesis related owing to endo-
carditis of the BioConduit. Among the other 43 patients
with non–prosthesis-related late deaths, 8 patients died of
cardiac causes, 1 of whom had recurrent endocarditis of
the mitral valve prosthesis (Shelhigh), with vegetations on
echocardiography. The overall survivals at 1 and 5 years
are 77.6% � 3.2% and 54.6% � 4.6%, respectively.
This information is presented in Figure 1 for the total group
and selectively for the patients having elective and emer-
gency operations. For the complete follow-up period, there
is a significant difference between the elective and emer-
gency groups (P¼ .003). After exclusion of the first 30 post-
operative days, this difference disappears (P ¼ .679).
Six (4.0%) patients required reoperation for significant
prosthesis dysfunction owing to endocarditis of the BioCon-
duit (n¼ 5) and false aneurysm (n¼ 1). Mean length of time
between the initial aortic root replacement and reoperation
was 21.7 months � 22.1 months. Three patients underwent
reoperation within 1 year after the initial root replacement,
and in all these cases the cause of reoperation was endocar-
ditis. During reoperation most patients received a second
Shelhigh BioConduit, except 1 patient who received a homo-
graft. One patient, known to have a false aneurysm, is being
followed up conservatively because she underwent multiple
sternal wound explorations, and a reoperation for false aneu-
rysm correction is estimated to be too high a risk. One patient
died after reoperation for endocarditis. One- nd 5-year free-
dom from reoperation is 76.4%� 3.2% and 50.8� 4.6% as
presented in Figure 2.
Endocarditis of the Shelhigh BioConduit was reported in
11 (7.3%) patients. Five of these patients were reoperated on
and only 1 p tient died 3 months after the r operation, as de-
scribed earlier. Six patients were not referred for surgery by
their cardiologist and were treated medically, and all these
patients died subsequently. Two of them had autopsy, which
FIGURE 1. Survival curve after aortic root replacement with a Shelhigh
BioConduit for the elective, emergency, and total group.
FIGURE 2. Freedom from reoperation after aortic root replacement with
a Shelhigh BioConduit.
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Figure 2. Freedom from reop ration after aortic ro t replace  ith a Shelhigh bioconduit
Endocarditis of the Shelhigh bioconduit was reported in 11 patients (7.3%). Five of 
these patients were reoperated on and only one patient died 3 months after the 
reoperation, as described earlier. Six patients were not referred for surgery by their 
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cardiologist and were treated medically, and all these patients died subsequently. Two 
of them had autopsy, which confirmed endocarditis of the bioconduit. The indication 
for the initial aortic root replacement was prosthetic valve endocarditis for one 
patient, and the rest of the patients had new-onset endocarditis of the bioconduit 
with Staphylococcus and Enterococcus as predominant microorganism. The incidence 
of late endocarditis was lower in the rethoracotomy group (2.1 %) than in the non-
rethoracotomy group (7.9 %; p = 0.2297). Nine (81.8 %) of the 11 patients who had 
new onset endocarditis received the implant after the year 2003. Mean interval 
between initial aortic root replacement and new onset endocarditis was 18.9 months 
± 20.4 months, with a median of 9.3 months.
Follow-up imaging was mostly done by computed tomography scan. This was available 
for 82 patients (81.2%) and showed the 2 cases of false aneurysm as described earlier. 
Distal native aorta diameter increased in 5 patients without indication for reoperation. 
Dilatation or calcification of the pericardial tube was not observed. Echocardiographic 
evaluation of the bioconduit function was performed by most referring cardiologists 
when there was a clinical indication. A recent echocardiographic assessment of the 
bioconduit function was available in 43 survivors (42.6%). Apart from adequate 
valve function, this showed previously mentioned vegetations and false aneurysms. 
Besides, there were 2 patients with moderate aortic regurgitation and 3 patients with 
moderate aortic stenosis (mean gradient 50.7 ± 12.9 mmHg) during a mean follow-up 
of 3.1 years.
DISCUSSION
The aortic homograft was the first complete biological composite valved graft used in 
our center, predominantly for endocarditis and for relatively young patients. Its limited 
donor availability and suboptimal long-term durability has made us less enthusiastic to 
use this graft (2). As an alternative, commercially available stentless biological valved 
conduits were introduced, which have the benefit of being readily available off the 
shelf in all sizes. The Shelhigh bioconduit is such a biological composite valve graft. We 
used this bioconduit predominantly in the elderly patient (mean age 71 years) with 
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degenerative aortic root disease, but also in patients with aortic valve endocarditis 
(mean age 64 years), because of its complete biological aspect.
The limited initial results about the Shelhigh bioconduit in the literature were 
promising with good clinical and echocardiographic results, even in patients with 
active infective endocarditis (9-11). Recently, the US Food and Drug Administration 
(FDA) published a preliminary public health notification on possible contamination 
and malfunction of devices manufactured by Shelhigh, Inc. (12). After this, Carrel and 
associates reported several precarious cases of reoperations and unexplained deaths 
occurring after implantation of the Shelhigh bioconduit (13, 14). In their total group 
of 115 patients who received a Shelhigh bioconduit, 7 patients (6.1 %) had ‘sudden 
disastrous findings’ and 4 of them required emergency reoperation. In our series 
11 patients (7.3 %) had blood culture positive endocarditis and 5 of them required 
reoperation. Patients with endocarditis of the bioconduit who were not referred for 
surgery all died, and in 2 of these patients endocarditis was proven by autopsy. Our 
aggressive rethoracotomy policy did not have a significant effect on late endocarditis 
because the incidence of late endocarditis was lower in the rethoracotomy group than 
in the non-rethoracotomy group (2.1 % vs 7.9 %; p = 0.2297).
Beside endocarditis of the bioconduit, there were 2 patients with false aneurysm 
formation at the bioconduit and the number of patients with sudden, unexplained 
death was relatively high (9.3 %). Unfortunately, we could not find detailed 
information about the cause of death of these patients (mean age, 75.8 ± 8.4 years). 
It is conceivable that there might be some sudden, unexplained deaths because of 
endocarditis of the bioconduit. If we look at the 7.3 % incidence of endocarditis of 
the Shelhigh bioconduit in this study and in our previous homograft series, we note 
that the incidence of endocarditis of the homograft was only 3.2 %, despite a higher 
number of patients with endocarditis as the initial indication for surgery (2). A true 
comparison, however, is not valid, because the patient groups are not comparable. It is 
important to note that most of the endocarditis of the bioconduit cases (81.8 %) were 
Shelhigh conduits implanted after 2003. In 2007 the Food and Drug Administration 
published its preliminary public health notification. As a consequence, we have now 
strictly limited the implantation of the Shelhigh bioconduit for extensive aortic valve 
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endocarditis complicated by annular abscesses. In elective setting, we are in search of 
an alternative for the Shelhigh bioconduit.
Because of the lack of published clinical experience reports specifically about the 
Shelhigh bioconduit, we sought literature concerning other stentless biological 
conduits (15-19). Compared with these reports, our operative mortality of 1.7 % and 
hospital mortality of 13.7 % satisfies in a group with a mean age of 71 years, extended 
graft repair of the ascending aorta (41 %) and involved aortic arch repair (52 %) with 
aortic valve endocarditis (11.4 %) or acute type A dissection (6.3 %) in 17.7 % of the 
patients. The incidence of endocarditis of the stentless biological conduits in these 
reports is lower than our 7.3 %. The freedom from reoperation is comparable with 
these reports. 
In conclusion, although perioperative results are satisfactory, the follow-up results are 
worrisome and the relatively high incidence of endocarditis of the Shelhigh bioconduit 
in our retrospective single center analysis has led us to change our policy. There is a 
need for other centers to report their experiences as well, in order to draw more solid 
conclusions. Patients who have received the Shelhigh bioconduit should be monitored 
closely and long-term results should be evaluated. 
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ABSTRACT
Objective: We retrospectively evaluated our results with the BioValsalva conduit 
(Vascutek Terumo, Renfrewshire Scotland), a stentless porcine valve incorporated in a 
three-layered prosthetic graft. 
Methods: From July 2008 through April 2011, 102 patients with a mean age of 70.9 ± 
7.3 years underwent aortic root replacement with a BioValsalva conduit. The indication 
for surgery was aneurysmal disease of the aorta in 81 patients (79.4 %), aortic valve 
endocarditis in 15 patients (14.7 %), acute type A aortic dissection in 4 patients (3.9 
%) and other causes in 2 patients (2.0 %). In 26 patients (25.5 %) the intervention was 
a reoperation.
Results: Overall hospital mortality was 4.9 % (n = 5; 95 % confidence limit (CL), 1.6 
% - 11.1 %). Cause of death was cardiac failure in 2 patients, multiple organ or renal 
failure in 2 patients and tamponade in 1 patient. Mean follow-up was 8.1 months. 
During follow-up 3 deaths occurred (3.1 %), because of mediastinitis, cardiac ischemia 
and arrhythmia. The overall survival at 3 and 12 months was 95.9 % (95 % CL, 92.0 
% - 99.9 %) and 92.1 % (95 % CL, 85.7 % - 98.9 %) respectively. Three patients (3.1 %) 
had new-onset endocarditis of the BioValsalva conduit; 2 of these patients required a 
reoperation and 1 patient received antibiotic treatment only.
Conclusions: Retrospective analysis of the BioValsalva conduit for aortic root 
replacement in more than 100 consecutive patients demonstrated satisfactory initial 
results, with low mortality and acceptable low morbidity rates. Follow-up is mandatory 
and long-term results are to be awaited.
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INTRODUCTION
The composite valved graft used at the first aortic root replacement contained a 
mechanical valve; currently there are also biological valved conduits that can be used 
for aortic root replacement (1). The increasing age of patients and the thromboembolic 
complication risk because of the necessary use of a vitamin K antagonist along with 
mechanical valves advanced the need for biological valved conduits in the treatment 
of aortic root pathology conditions. Currently, a few biological valved conduits are 
available; they have the benefit of being readily available off the shelf in all sizes 
and do not require lifelong oral anticoagulation and subsequently present a lower 
thromboembolic risk (2). After disappointing results with the Shelhigh bioconduit 
(Shelhigh, Millburn, NJ), the BioValsalva conduit (Vascutek Terumo, Renfrewshire 
Schotland) was introduced in our center (3-5). This conduit is a combination of 
a Valsalva graft, already introduced in 2000, and a stentless porcine valve (Elan, 
Vascutek, Terumo) (6). The coated polyester (Dacron) Valsalva graft has to be stored 
in a dry environment and the biological valve must be stored in glutaraldehyde. This 
problem is solved by modifying the coated polyester Valsalva graft into a three-layered 
graft, which allows storage in glutaraldehyde and preserves its impermeability (Figure 
1). This vascular graft is made of an uncoated Gelweave (Vascutek, Terumo) polyester 
inner layer and a polytetrafluoroethylene outer layer, which are glued together with 
a central, self-sealing elastomeric membrane that makes the graft impermeable (7). 
The proximal part of the graft has the Valsalva shape, mimicking the sinuses of the 
aortic root with reduction of tension on the coronary buttons and improvement of 
coronary flow and valve hemodynamics (8, 9). This new composite bioprosthetic valve 
has been used for various aortic root pathologic conditions. In this article, we describe 
and analyse our initial experience in 102 patients.
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Figure 1. (A) BioValsalva conduit: a stentless porcine valve incorporated in a 3-layered prosthetic 
graft. (B) View from inside.
First 102 Patients with the BioValsalva Conduit for Aortic Root Replacement
111
8
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
PATIENTS AND METHODS
Patients
From July 2008 through April 2011, 102 consecutive patients with a mean age of 
70.9 years (range 34 - 85 years) underwent aortic root replacement with a BioValsalva 
conduit. There were 69 male (67.6 %) and 33 female (32.4 %) patients. The Ethics 
Committee at our institution approved this retrospective cohort study and waived 
the need for patient consent. The aortic root pathologic conditions treated using 
this composite bioprosthetic valve consisted of 81 aneurysms (79.4 %), 14 cases of 
prosthetic valve endocarditis (13.7 %), 4 acute type A aortic dissections (3.9 %), 2 
false aneurysms after previous aortic root replacement (Shelhigh) (2.0 %) and one 
native valve endocarditis with root abcess (1.0 %). The intervention was a reoperation 
after previous cardiac operations in 26 patients (25.5 %) the majority of whom (23 
patients) had previous aortic valve operations. Twelve patients (11.8 %) were treated 
under emergency conditions because of type A aortic dissection or prosthetic valve 
endocarditis. Comorbid medical conditions consisted of hypertension (n = 64, 62.8 
%), chronic obstructive pulmonary disease (n = 16, 15.7 %), diabetes (n = 12, 11.8 
%), renal dysfunction (n = 10, 9.8 %; serum creatinine level > 120 μmol/L), previous 
cerebrovascular accident or transient ischemic attack (n = 7, 6.9 %) and Marfan 
syndrome (n = 2, 2.0 %). Mean aortic diameter for aneurysmal disease was 54.8 ± 
8.3 mm (range 40 - 85 mm). Concomitant aortic valve pathologic conditions consisted 
of severe aortic regurgitation (grade ≥ 3) in 43 patients (42.2 %), moderate to severe 
aortic valve stenosis (mean gradient, 67.4 ± 35.7 mmHg) in 24 patients (23.5 %). A 
bicuspid aortic valve was present in 16 patients (15.7 %). Preoperative mitral valve 
regurgitation (grade ≥ 3) as a comorbid cardiac lesion was present in 7 patients (6.9 %) 
and coronary artery disease was seen in 25 patients (24.5 %). Pertinent patient data 
are given in Table 1.
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Table 1. Patient characteristics (n = 102)
No. %
Age (years)
     mean (SD ; range) 70.9 (7.3 ; 34-85)
Gender
     male 69 67.6
NYHA class
•	 I 6 5.9
•	 II 54 52.9
•	 III 36 35.3
•	 IV 6 5.9
Indication
•	 Aneurysmal disease 83 81.4
- degenerative 81
- false 2
•	 Aortic valve endocarditis 15 14.7
- prosthetic 14
•	 Acute type A dissection 4 3.9
Valvular disease
•	 Aortic valve regurgitation
- grade I 40 39.2
- grade II
- grade III
- grade IV
•	 Aortic valve stenosis
  mean gradient, mmHg (SD;range)
•	 Mixed aortic valve lesion
•	 Bicuspid aortic valve
19
27
16
22
67.4 (35.7 ; 23-165)
2
16
18.6
26.5
15.7
26.2
2.0
15.7
Reoperation 26 25.5
•	 Previous aortic valve operation 23
Comorbid medical conditions
     Hypertension 64 62.8
     COPD 16 15.7
     Diabetes 12 11.8
     Renal insufficiency 10 9.8
     CVA 7 6.9
     Marfan syndrome 2 2.0
SD = standard deviation; NYHA = New York Heart Association; COPD = Chronic Obstructive 
Pulmonary Disease; CVA = Cerebral Vascular Accident.
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Procedure
Full aortic root replacement for composite valve graft insertion with the button 
technique for reattachment of the coronary ostia was used in all patients in 
combination with standard cardiopulmonary bypass and carbon dioxide insufflation in 
the operative field. The aortic cannulation site was mainly the distal ascending aorta 
(n = 68) or the common femoral artery (n = 33) in case of a reoperation or a type A 
aortic dissection. Cold crystalloid antegrade cardioplegia was administrated through 
the aortic root or coronary ostia selectively with intermittent cardioplegic reinfusion if 
needed. During cardioplegic arrest, the myocardial septal temperature was measured 
and kept around 10 °C using a Shumway cold line. Depending on the pathologic 
condition of the aorta and the location and extension of the lesion, a distal clamp could 
be used in 62 cases (60.8 %). If the lesion extended to the aortic arch, necessitating 
open distal anastomosis, deep hypothermic circulatory arrest was used in 11 patients 
(10.8 %) and antegrade selective cerebral perfusion with mild hypothermia was used 
in 29 patients (28.4 %), by surgeon preference (10,11). The proximal suture technique 
was the same in all cases and consisted of suturing the prosthetic sewing ring to 
the annulus with interrupted pledgeted 2-0 braided polyester mattress sutures, and 
a continuous 5-0 polypropylene suture was used to reinforce the proximal annular 
anastomosis against anastomotic leakage. After measuring the appropriate position 
for the coronary ostia, an opening was made with a blade and not with cautery, 
because of the polytetrafluoroethylene outer layer. Afterward, circular holes were 
created with a 4-mm punch and the coronary ostia were reattached with a continuous 
6-0 polypropylene suture.
The diameter of the implanted BioValsalva conduits ranged from 21 to 27 mm with a 
median of 25 mm. Aortic root and distal ascending aorta replacement was done in 64 
patients (62.8 %). Root replacement and ascending aorta with partial arch replacement 
was effectuated in 32 patients (31.4 %). Finally, aortic root, ascending aorta, and total 
arch replacement with or without elephant trunk was performed in 6 patients (5.9 
%). In 37 patients (36.3 %) a woven vascular graft was used as an extension of the 
BioValsalva conduit and the native downstream aorta. The graft diameter ranged from 
24 to 32 mm with a median of 26 mm.
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Concomitant procedures included planned coronary artery bypass grafting in 25 
patients (24.5 %), coronary artery bypass grafting because of technical problems in 5 
patients (4.9 %), mitral valve repair or replacement in 4 patients (3.9 %), combination 
of planned coronary artery bypass grafting and mitral or tricuspid valve procedures 
in 3 patients (3.6 %) or other procedures such as carotid endarterectomy or rhythm 
procedures, in 3 patients (3.6 %). Operative data are given in detail in Table 2.
Table 2. Operative characteristics (n = 102)
No. %
Emergency
     Elective 90 88.2
     Emergent 12 11.8
 Cannulation site
     Ascending aorta
     Common femoral artery
     Axillary artery
68
33
1
66.6
32.4
1.0
Perfusion data
     CPB and distal clamp
     DHCA
     ASCP
     CPB time  min, mean (SD ; range)
     Aortic clamp time
     DHCA time
     ASCP time
62
11
29
194.0 (79.0 ; 81 - 542)
133.0 (45.9 ; 60 - 288)
20.6 (4.5 ; 15 - 30)
37.8 (33.3 ; 19 - 194)
60.8
10.8
28.4
Extent of aorta replacement                 
     + Ascending 
     + Ascending and partial Arch
     + Ascending and total Arch
     + Ascending, total Arch and ET
64
32
5
1
62.8
31.4
4.9
1.0
Concomittant procedure
     CABG planned 25 24.9
     CABG unplanned 5 4.9
     Mitral valve repair or replacement 4 3.9
     Combination 3 2.9
     Other 3 2.9
CPB = cardiopulmonary bypass; DHCA = deep hypothermic circulatory arrest; ASCP = antegrade 
selective cerebral perfusion; SD = standard deviation; ET = elephant trunk; CABG = coronary 
artery bypass grafting.
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Follow-up
Recent (< 6 months) information about the status of all hospital survivors was 
collected from the referring cardiologist, from visits to our outpatient clinic or our 
cardiology department, or from their general physicians. February 1 and May 1, 2011 
was the closing interval for follow-up and included physical examination, computed 
tomography, echocardiography and chest radiography, if available. Endpoints of the 
study were death, valve-related death, reoperation for valve failure, and endocarditis 
of the BioValsalva conduit. These endpoints were defined according to the guidelines 
reported by Akins and associates (12).
Data Analysis
Retrospective review was performed on the data of all consecutive patients who 
underwent aortic root replacement with the BioValsalva conduit. Quantitative data 
are presented as mean ± standard deviation. Odds Ratio’s (OR) and Fisher’s exact p 
value were used for comparison. Kaplan-Meier survival curves were used for analysis 
of survival times. Precision was indicated by 95 % confidence limits (CL). All statistical 
analyses were done by R (version 2.9 www.r-project.org).
RESULTS
Early Results
There were no intraoperative deaths. Overall hospital mortality was 4.9 % (n = 5; 95 % 
CL, 1.6 % - 11.1 %), 3.3 % (n = 3/90) of which was for elective procedures and 16.7 % 
(n = 2/12) was for emergent procedures (p = 0.104). The emergent cases in which the 
patients died were initially operations for acute type A aortic dissection or prosthetic 
valve endocarditis, and the cause of death was ischemic cardiac failure for both. 
They died within 3 postoperative days. The cause of in-hospital deaths in elective 
operations (mean age of patients, 78 years, died after a mean postoperative period 
of 65 days) included multiple organ failure, renal failure, and tamponade. Cause of in-
hospital death is summarized in Table 3. The hospital mortality for patients with aortic 
aneurysm (non-dissection and non-endocarditis) who underwent elective operations 
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was 3.7 % (n = 3). In six patients (5.9 %), intraoperative problems required a second 
cardiopulmonary bypass run and in 4 of these patients a second crossclamp of the 
aorta with cardioplegic arrest was necessary. The main reason was to obtain control of 
bleeding from the proximal suture line or coronary ostium anastomosis.
Table 3. Causes of Early and Late death (n = 8)
Causes of death No. %
Early : In hospital 5 4.9
     Intraoperative 0 0.0
     Postoperative, hospital 
       - Elective : 
                         - cardiac tamponade 
 - multiple organ failure
 - renal failure
 
       - Emergent :  
                            - ischemic cardiac failure
5
          
3
          1
          1
                      1
2
            2
4.9
Late : Follow-up 3 3.1
     Mediastinitis/ False aneurysm 1                  1.0
     Cardiac 
- ischemic cardiac failure
- arrhythmia
2
          1        
          1
2.1
The median intensive care unit stay was 3 days (range 1 – 65 days). Fourteen patients 
(13.7 %) needed ventilatory support for more than 48 hours, and a tracheostomy 
was performed in 3 patients (2.9 %). A rethoracotomy was performed in 20 patients 
(19.6 %), mostly for excessive bleeding (n = 9) diffuse oozing (n = 4), or leakage from 
the coronary reattachment line (n = 2), cannulation site (n = 2) or the distal suture 
line (n = 1). Clinical signs of tamponade (n = 8) were also a predominant reason for 
rethoracotomy. A planned rethoracotomy within a few days after operation for removal 
of gauzes (n =3) was the third reason for rethoracotomy. Postoperative temporary 
hemodialysis was necessary in 4 patients (3.9 %). One of these patients died in the 
hospital; the others recovered and 1 patient needed long-term dialysis. 
New neurologic symptoms were observed in 6 patients (5.9 %). Ischemic cerebral 
accidents occurred in 5 patients and critical illness polyneuropathy was seen in 1 
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patient. The neurologic symptoms were all temporary and resolved completely. No 
patients in the stroke group died in the hospital.
Follow-up results
There were 97 hospital survivors and all except 1 patient were entered in the follow-
up study (99 % complete). The reason for lost to follow-up of 1 patient was emigration 
to another continent. Mean and median follow-up was 8.1 months and 4.6 months, 
respectively (range 1.8 - 31.5 months). Total follow-up was 67 patient-years. During 
follow-up 3 patients (3.1 %) died and all deaths occurred in the first postoperative year. 
Causes of death during follow-up are summarized in Table 3. One of these late deaths 
was after mediastinitis with involvement of the composite bioprosthetic valve and 
signs of a false aneurysm at the aortic root on computed tomography. The reoperation 
risk was too high for this 79-year-old patient because he was in poor clinical condition 
and it would be his third reoperation. He received great omentum plasty, refixation 
of the sternum, and antibiotic treatment, but unfortunately died 4 months later. The 
second patient died suddenly after ventricular tachycardia 12 months after the initial 
aortic root replacement, and the third patient after acute coronary syndrome during 
atrial fibrillation 6 months after the BioValsalva conduit implantation. Unfortunately 
there was no permission for autopsy. The overall survival at 3 and 12 months was 95.9 
% (95 % CL, 92.0 % - 99.9 %) and 92.1 % (95 % CL, 85.7 % - 98.9 %) respectively. This 
is presented in Figure 2. Univariate analysis showed a better overall survival for the 
aortic aneurysm group than for the other indications for operation (HazardRatio = 
0.16; 95 % CL 0.04 -0.67; p < 0.01). Multivariate analysis was not performed because 
overfitting would occur with this relatively low total number of endpoints.
Two patients (2.1 %) required reoperation for significant prosthesis dysfunction 
due to endocarditis of the composite bioprosthetic valve and three patients (3.1 %) 
needed a reoperation for mitral valve procedures. One patient had endocarditis of the 
composite bioprosthetic valve after percutaneous coronary intervention and received 
a new aortic root replacement with a composite bioprosthetic valve and the other 
patient had healed endocarditis after tooth extraction, with severe aortic regurgitation 
for which he received a biological aortic valve replacement. None of the patients died 
after a reoperation. Three- and 12-month freedom from reoperation for aortic valve 
or conduit was 100 % and 97.0 % (95 % CL, 91.2 % - 100 %). 
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of which was for elective procedures and 16.7% (n 2/12)
was for emergent procedures (p  0.104). The emergent
cases in which the patients died were initially operations
for acute type A aortic dissection or prosthetic valve
endocarditis, and the cause of death was ischemic cardiac
failure for both. They died within 3 postoperative days.
The cause of in-hospital deaths in elective operations
(mean age of patients, 78 years; died after a mean
postoperative period of 65 days) included multiple organ
failure, renal failure, and tamponade. Cause of in-
hospital death is summarized in Table 3. The hospital
mortality for patients with aortic aneurysm (nondissec-
tion and nonendocarditis) who underwent elective oper-
ations was 3.7% (n  3). In 6 patients (5.9%), intraopera-
tive problems required a second cardiopulmonary
bypass run, and in 4 of these patients a second cross-
clamp of the aorta with cardioplegic arrest was necessary.
The main reason was to obtain control of bleeding from
the proximal suture line or coronary ostium anastomosis.
The median intensive care unit stay was 3 days (range,
1–65 days). Fourteen patients (13.7%) needed ventilatory
support for more than 48 hours, and a tracheostomy was
performed in 3 patients (2.9%). A repeated thoracotomy
was performed in 20 patients (19.6%), mostly for exces-
sive bleeding (n  9), diffuse oozing (n  4), or leakage
from the coronary reattachment line (n  2), the cannu-
lation site (n  2), or the distal suture line (n  1)).
Clinical signs of tamponade (n  8) were also a predom-
inant reason for repeated thoracotomy. A planned re-
peated thoracotomy within a few days after operation for
removal of gauzes (n  3) was the third reason for
repeated thoracotomy. Postoperative temporary hemodi-
alysis was necessary in 4 patients (3.9%). One of these
patients died in the hospital; the others recovered and 1
patient needed long-term dialysis.
New neurologic symptoms were observed in 6 patients
(5.9%). Ischemic cerebral accidents occurred in 5 patients
and critical illness polyneuropathy was seen in 1 patient.
The neurologic symptoms were all temporary and re-
solved completely. No patients in the stroke group died
in the hospital.
Follow-Up Results
There were 97 hospital survivors and all except 1 patient
were entered in the follow-up study (99% complete). The
reason for loss to follow-up of 1 patient was emigration to
another continent. Mean and median follow-up was 8.1
months and 4.6 months, respectively (range, 1.8–31.5
months). Total follow-up was 67 patient-years. During
follow-up, 3 patients (3.1%) died and all deaths occurred
in the first postoperative year. Causes of death during
follow-up are summarized in Table 3. One of these late
deaths was after mediastinitis with involvement of the
composite bioprosthetic valve and signs of a false aneu-
rysm at the aortic root on computed tomography. The
reoperation risk was too high for this 79-year-old patient
because he was in poor clinical condition and it would be
his third reoperation. He received great omentum plasty,
refixation of the sternum, and antibiotic treatment, but
unfortunately died 4 months later. The second patient
died suddenly after ventricular tachycardia 12 months
after the initial aortic root replacement, and the third
patient died after acute coronary syndrome during atrial
fibrillation 6 months after the BioValsalva conduit im-
plantation. Unfortunately there was no permission for
autopsy. The overall survival at 3 and 12 months was
95.9% (95% CL, 92.0%–99.9%) and 92.1% (95% CL, 85.7%
98.9%) respectively. This is presented in Figure 2.
Univariate analysis showed a better overall survival for
the aortic aneurysm group than for the other indications
for operation (hazard ratio  0.16; 95% CL 0.04–0.67; p 
0.01). Multivariate analysis was not performed because
overfitting would occur with this relatively low total
number of endpoints.
Two patients (2.1%) required reoperation for signifi-
cant prosthesis dysfunction endocarditis of the composite
bioprosthetic valve, and 3 patients (3.1%) needed reop-
eration for mitral valve procedures. One patient had
Table 3. Causes of Early and Late Death (n  8)
Causes of Death No. %
Early: In hospital 5 4.9
Intraoperative 0 0.0
Postoperative, hospital 5 4.9
Elective 3
Cardiac tamponade 1
Multiple organ failure 1
Renal failure 1
Emergent: 2
Ischemic cardiac failure 2
Late: Follow-up 3 3.1
Mediastinitis/false aneurysm 1 1.0
Cardiac 2 2.1
Ischemic cardiac failure 1
Arrhythmia 1
Fig 2. Survival curve after aortic root replacement with a Bio-
Valsalva conduit.
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Figure 2. Survival curve after aortic root replacement with a BioValsalva conduit.
Endocarditis of the BioValsalva conduit was reported in 3 patients (3.1 %). Two of 
these patients underwent reoperations as described and survived. One patient 
received antibiotic treatment for 6 weeks and recovered with good aortic valve 
function. The indication for the initial aortic root replacement was aortic aneurysm, 
and all these patients had new-onset endocarditis of the composite bioprosthetic 
valve, with Streptococcus and Enterococcus as predominant microorganisms. The 
interval between initial aortic root replacement and new-onset endocarditis was 22, 
8 and 3 months, respectively. 
Follow-up imaging was mostly done by computed tomography and showed growth 
of descending aorta diameter in 3 patients; 2 patients underwent endovascular 
intervention. There were no pathologic signs on the Biovalsalva prosthesis. 
Echocardiographic evaluation of the composite bioprosthetic valve function was 
performed by most referring cardiologists when there was a clinical indication. 
Apart from adequate valve function, this showed previously mentioned aortic valve 
dysfunction and new-onset mitral valve regurgitation. There was no moderate or 
severe aortic regurgitation observed and most patients had no aortic regurgitation. 
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DISCUSSION
Both the increasing age of patients and the lowered threshold for biological valves 
will advance the need for biological valved conduits in aortic root pathologic 
conditions. These biological conduits have the advantage of being readily available 
off the shelf in all sizes and do not require lifelong oral anticoagulation resulting in 
low thromboembolic complication risk (2). A number of biological valved conduits 
are commercially available. Initially we used the Shelhigh bioconduit, but after 
a disappointing incidence of endocarditis with this graft (7.3 %), we switched to 
the BioValsalva (Vascutek Terumo) conduit (3-5). This is a stentless porcine valve 
incorporated into a three-layered graft with a Valsalva shape at the proximal part. 
The limited initial results with the BioValsalva conduit in the literature are promising, 
with good clinical and echocardiographic results, but there are only a small number 
reports (9, 13-16). In this retrospective initial evaluation, we observed that the overall 
hospital mortality is 4.9 % and for patients undergoing elective procedures, the 
hospital mortality is 3.3 %. We lost 2 patients who underwent emergent operations 
because of ischemic cardiac failure and 3 patients who underwent elective operations 
because of multiple organ failure, renal failure and, unfortunately, a late recognised 
tamponade in the last patient. Compared with our Shelhigh (13.7 %) or mechanical 
composite valve group (3.2 %) it is an acceptable number of hospital mortality (3, 17). 
However a direct comparison between these reports would not be fair because the 
patient groups are not comparable. Maybe the Shelhigh bioconduit group is most 
comparable. Other, smaller series of Biovalsalva conduit reported a hospital mortality 
rate of 4.7 to 8.0 %, which is comparable to our 4.9 % (9, 13-16). Compared with other 
reports on biological valved conduits, our hospital mortality is satisfactory in a group 
with a mean age of 71 years, extended graft repair of the ascending aorta and involved 
aortic arch repair (37.3 %) with aortic valve endocarditis (14.7 %) (18-21). Again, one 
should note that the patient groups in these comparisons may be different. 
There were 5 patients with postoperative ischemic cerebral accidents. During their 
operations, a distal aortic clamp was used most often and the arterial cannulation site 
was predominantly in the distal ascending aorta, but 2 patients had peripheral arterial 
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cannulation. All patients had only ascending aorta replacement, with the exception of 
1 patient who also received an aortic arch replacement. Fortunately, all neurological 
symptoms resolved completely before discharge. During follow-up there were no 
thromboembolic events reported. 
Reoperation for BioValsalva conduit dysfunction was needed in 2 patients because 
of endocarditis. Endocarditis of the BioValsalva conduit developed after a procedure 
(tooth extraction, percutaneous coronary intervention) in these patients, despite 
prophylactic antibiotics, and created severe aortic regurgitation for which reoperation 
was necessary. The reoperations were uneventful. Compared with other series of 
Biovalsalva conduit use, the reoperation percentage is acceptable (9, 13-16). Severe 
mitral valve regurgitation developed during follow-up in 3 other patients, for which 
they needed mitral valve procedures. One of these patients had moderate mitral valve 
regurgitation before aortic root replacement, which was aggravated postoperatively. 
The other 2 patients had new-onset mitral valve regurgitation, and 1 of these patients 
was initially operated on for prosthetic valve endocarditis with root abcess. 
Endocarditis of the BioValsalva conduit was diagnosed in 3 patients (3.1 %). Two 
patients needed a reoperation as described. The last patient received antibiotic 
treatment for 6 weeks and recovered. The control echocardiography showed a good 
functioning composite bioprosthetic valve without aortic regurgitation. The incidence 
of endocarditis of the BioValsalva conduit (3.1 %) is comparable to the incidence of 
endocarditis in our homograft (3.2 %) (n = 213), Ross procedure (1.9 %) (n = 103), and 
mechanical valve conduit groups (3.8 %) (n = 528) (17, 22, 23). In our institution we 
use the homograft conduit only for patients with extensive aortic root abcess; for all 
other aortic root pathologic conditions, the BioValsalva conduit is our preferred graft 
for patients older than 65 years and when the patient’s preference is a biological valve.
As with every initial evaluation report the follow-up period is relatively short and the 
brief echocardiographic data are the limiting factor in this retrospective study.
In conclusion, the preliminary initial results of the BioValsalva conduit in our series of 
102 patients are satisfactory. The relatively low mortality and morbidity numbers are 
promising, but close follow-up is mandatory and long-term results are awaited.
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The aortic root is a complex hemodynamic unit consisting of different components, like 
the semilunar valvular leaflets, the sinuses of Valsalva and the interleaflet triangles. 
These are continuously changing and moving in harmony during each cardiac cycle 
(1). Its function is to connect the left ventricle with the ascending aorta and direct the 
blood in a unidirectional way and promote coronary artery perfusion. This function can 
be disturbed at different levels of the aortic root by different pathological processes, 
like degenerative valvular disease, aneurysm of the aortic root, dissection of the aortic 
wall with destruction of the aortic root or aortic valve endocarditis with root abscess. 
In most situations the diseased aortic root is replaced together with the aortic leaflets 
by a valved conduit. Specific pathological conditions of the aortic root, like aneurysmal 
dilatation, have less effect on the aortic leaflets and these morphologically normal 
appearing leaflets can be spared.
The need for biological valved reconstructions of the aortic root is increasing since 
the patient population is ageing. These biological valved solutions for aortic root 
replacement avoid the need for permanent oral anticoagulation. This is a major 
advantage in terms of bleeding, risk of thromboembolism and patient convenience.
This dissertation contains the results of aortic root reconstructions with different 
biological valved substitutes and valve-sparing aortic root replacement with the 
reimplantation technique practiced in the St. Antonius Hospital, Nieuwegein. These 
studies are retrospective cohort evaluations and have the disadvantage of possible 
bias, such as selection or information bias. The aim of this thesis is to present the 
hospital outcomes and examine follow-up results in order to answer the previously 
mentioned research questions.
In Chapter 2 we studied the mid-term results of aortic root replacement with 
cryopreserved homografts. This biological conduit was predominantly implanted in 
patients with aortic valve endocarditis (native and prosthetic) and in young patients 
with aortic valve or root pathology who preferred not to use life-long anticoagulation. 
In the beginning of aortic homograft use in our institution, the aim was to avoid a 
prosthetic conduit in active endocarditis, because of the higher rate of recurrent 
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endocarditis when mechanical or xenograft valves were used (2, 3). Nowadays, 
the choice of valve prosthesis in native and prosthetic valve endocarditis remains 
controversial (4, 5). Several reports have shown that the type of prosthesis used is not 
an important factor in achieving good early and long-term results if radical excision of 
all infected and necrotic tissue can be achieved and appropriate antibiotic treatment 
is administered (6-10). Nonetheless, in patients who have periannular abscess and 
annular destruction, homografts are still our choice of conduits, because of the 
pliable nature of the homograft that makes it easier to handle than other materials, 
and its additional periannular tissue that can be used to patch defects created by the 
resection of the abscesses and help restore atrioventricular continuity (11-13). It has 
also been reported that aortic homografts reduce the risk of recurrent endocarditis 
(12). Our mid-term evaluation supports the low recurrence rate of endocarditis of 
homografts (3.2 %). In contrast, recent reports show no significant difference in 
recurrent endocarditis rates between different types of prostheses (9, 10).
With a mean follow-up of nearly six years, our mid-term results are comparable to 
other reports (14-16). We observed that the survival curve declines after 8 to 10 
years and is worse in the endocarditis group. Further follow-up of our data is needed 
to present the exact long-term results of our aortic homografts. Literature reports 
on long-term results (mean follow-up > 10 years) of homografts show comparable 
survival curves, with a decline of survival after 10 years (14-16). The initial expectation 
of life-long durability of aortic homografts has not been achieved according to these 
long-term studies.
During follow-up, 9.3 % of the hospital survivors required a reoperation for significant 
homograft dysfunction. This was predominantly for structural valve deterioration. 
One third of these patients required a reoperation within five years after implantation 
of the aortic homograft. These ‘early’ reoperations, in a patient group with a 
mean age of 51 years, and the limited durability of homografts have changed our 
indication to use an aortic homograft in young patients. In our review, reoperations 
for homograft dysfunction carried a high mortality risk (28.6 %), especially in cases of 
homograft endocarditis. Our aggressive strategy to remove the complete homograft 
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conduit might be the cause of this. Recent reports show that the mean period of 
initial homograft implantation and reoperation is around 8 to 10 years (14-16). The 
reoperation risk is acceptable according to these reports (3.8 %) (17-19). It is not 
clear if this reoperation risk is due to a less aggressive surgical approach, such as 
replacement of the deteriorated valves, instead of the whole aortic root. Either way, a 
reoperation on a calcified homograft root is a challenge for the surgeon and a risk for 
the patient. All this has influenced our strategy for aortic homograft use. Nowadays, we 
only implant an aortic homograft in aortic valve endocarditis with annular abscesses. 
Aortic homografts are no longer advised for young patients with aortic root disease, 
because of their limited durability and high reoperation risk.
 
In Chapter 3 the medium-term outcome of aortic full root replacement with the 
pulmonary autograft and implantation of a homograft in the right ventricular outflow 
tract, the so-called modified Ross procedure is studied. This is accomplished in young 
patients (mean age 35 years) with aortic valve or root pathology and the wish not 
to use oral anticoagulation. There was no hospital mortality and the morbidity rate 
was low and satisfactory, despite the extensive double valve surgery. Strict patient 
selection and young patient age with low comorbidity played an important role in 
these rates. The overall survival at 10 years was 97.3 %, which is satisfactory. El-
Hamamsy et al. and Bekkers et al. reported studies with a mean follow-up of more 
than 10 years and both had comparable survival rates at 10 years (97 % and 95 %) (16, 
20). The El-Hamamsy group demonstrated that the survival of the autograft group was 
even comparable with the matched population for age and sex.
During a mean follow-up of six years, 4.8 % of the patients with a modified Ross 
procedure needed a reoperation for secondary regurgitation of the autograft, due 
to dilatation at the sinotubular junction or annular dilatation. These dilatation levels 
emphasize the weak points of the pulmonary autograft with a lack of a sinotubular 
junction and an anatomic ventriculo-arterial junction. Reinforcement of the 
annulus or adjustment of the diameter to the body surface area of the patient has 
been recommended for prevention of autograft regurgitation (21, 22). Since these 
recommendations a reinforcement ring or a reduction annuloplasty is used when the 
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annulus is dilated. Most of the reoperated autografts did not have a reinforcement 
ring. Recent evaluation of the German-Dutch Ross Registry showed that surgical 
autograft stabilization techniques preserve autograft function and result in significantly 
lower reoperation rates (23). In this registry, the autograft root replacement without 
reinforcement was associated with a six times increased reoperation rate compared 
to the autograft root replacement with reinforcement (p < 0.001). 
A reoperation for pulmonary homograft dysfunction was necessary in only one 
patient, because of significant stenosis. Echocardiographic follow-up showed 
significant increase in pulmonary flow velocities at the level of the homograft leaflets, 
without clinical symptoms. Systematic oversizing of the pulmonary homograft, low (< 
10 years) donor-patient age mismatch and the use of anti-inflammatory drugs have 
been recommended to reduce the risk of pulmonary homograft stenosis (16).
A rare complication after autograft dilatation is illustrated in Chapter 4 with a 
chronic type A dissection secondary to pulmonary autograft root dilatation, because 
of patient delay. This case underlines the importance of periodic and systematic 
echocardiographic evaluation of the autograft and the pulmonary homograft for 
prevention of severe late events.
Literature reports with long-term results after the modified Ross procedure show 
an increase in the reoperation rate in the second decade, after the initial operation 
(16, 20, 24). Although our reoperation rate is acceptable for now, we need further 
follow-up to assess the long-term reoperation rate of our modified Ross group. 
Bekkers et al. demonstrated that reoperations on the autograft can be done with 
low mortality and morbidity (20). El-Hamamsy et al. have demonstrated in a unique 
randomized controlled trial of autograft versus homograft aortic root replacement 
that the freedom from need of aortic root reoperation and freedom from need of any 
reoperation supported (p = 0.0003) the autograft group (16). This approves the use 
of a modified Ross procedure in young patients in comparison to aortic homografts. 
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In conclusion, the modified Ross procedure is still an option for young patients since 
the early and mid-term results are good, with the majority of patients having a normal 
life without anticoagulation. According to literature, long-term survival is excellent 
(16, 20, 24). Nevertheless, young patients have to be informed that a reoperation 
may become necessary in the future. The rate of reoperation can be reduced by using 
annular or sinotubular reinforcement of the autograft. It is therefore mandatory for 
strict follow-up of Ross patients with repeat echocardiographic evaluations of the 
autograft and the pulmonary homograft.
In some pathological conditions of the aortic root, like aneurysmal dilatation, the aortic 
valve leaflets are morphologically normal. These patients have aortic regurgitation 
secondary to dilatation of the ventriculo-aortic junction and/or sinotubular junction. 
In these situations the morphologically normal aortic leaflets can be spared using 
the reimplantation method. Chapter 5 evaluates our results with valve-sparing aortic 
root replacement with the reimplantation technique. Although there were some 
modifications of this technique over the years, especially modifications to mimic the 
sinuses of Valsalva, we continued using the first method described (25). In almost 
half of the cases the prosthetic Dacron graft type was a Valsalva graft (Gelweave 
Valsalva, Vascutek, Renfrewshire, Scotland), because there are finite element studies 
and magnetic resonance imaging reports illustrating the importance of neosinuses of 
Valsalva in a prosthetic graft in terms of reduced stress on the leaflets and reduced 
stress at the coronary button anastomoses and a near physiologic flow pattern in the 
neo aortic root (26-29). These neosinuses of Valsalva are presumed to improve the 
spared valve function and durability and decrease the incidence of postoperative 
complications, such as bleeding from the reimplanted coronary ostia and late 
pseudoaneurysm formation. In our mid-term evaluation, with a mean follow-up of 
more than five years, there was no significant difference between the type of graft 
and reoperation for recurrent aortic regurgitation. Further follow-up is needed to 
demonstrate a potential benefit of neosinuses of Valsalva.
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This technique was used mainly in aneurysmal aortic root pathology. After gaining 
experience, the indication was expanded to type A aortic dissection (17.3 %) with 
unaffected aortic leaflets. Although we had no hospital deaths and the morbidity rate 
was low, it is a subject of debate whether a longer and more complex operation, like 
valve-sparing aortic root replacement with the reimplantation technique, should be 
used in high risk patients with acute type A aortic dissection. However, numerous 
reports show that valve-sparing aortic root reconstruction does not compromise 
survival or perioperative risk in acute type A aortic dissection (30-34). Our results also 
indicate the safe use of this technique in type A dissection patients. 
This technique is also used in patients with Marfan syndrome (16.1 %). Initially there 
were concerns regarding the appropriateness of aortic valve-sparing in these patients 
with connective tissue disorder, but the experiences of several investigators suggests 
that valve-sparing aortic root replacement in Marfan patients is safe and durable (35-
37). Our cohort also showed a good survival of Marfan patients after valve-sparing 
aortic root replacement with the reimplantation technique. Only one Marfan patient 
needed a reoperation for recurrent aortic regurgitation. 
In our series, the freedom from reoperation at five years was 86.8 % (95 % CL, 78.7 
% - 95.8 %). During follow-up 8.6 % of the patients with valve sparing aortic root 
replacement with the reimplantation technique needed a reoperation for recurrent 
severe aortic regurgitation. Half of these reoperated patients were initially operated 
in the early, learning curve phase of valve sparing aortic root replacement with the 
reimplantation technique. Compared to the results with high volume centres with 
longer follow-up, our freedom from reoperation at five years is similar and satisfactory 
(38-41). Only the group of David reports an excellent rate of freedom from reoperation 
at 5 years of 99.7 % (38). 
If permanent oral anticoagulation is undesirable then valve-sparing aortic root 
replacement with the reimplantation technique is a good option in relatively young 
patients (mean age 51.9 years) with preserved aortic leaflets. Our mid-term evaluation 
encourages the use of the reimplantation technique. Long-term results are to be 
awaited, but literature reports with long-term results are promising (38-40). 
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Stentless aortic valves have comparable hemodynamic performances like the 
homograft or autograft (42-44). They become more durable and are readily available 
in various sizes. The increasing age of the Western population is also increasing the 
need for biological valved solutions for aortic root pathology. Therefore, a stentless 
biological valved conduit seems to be the next step in the evolution of biological 
valved aortic root reconstruction. Chapter 7 evaluates our experience with the totally 
biological Shelhigh conduit. After limited, but good initial reports in the literature, 
the Shelhigh conduit was used in our centre predominantly in elderly patients (mean 
age 71 years) with aortic root pathology and as an alternative to aortic homograft in 
cases of aortic valve endocarditis (45, 46). The results showed an overall in-hospital 
mortality of 13.7 %. For elective surgery of aortic root aneurysms this was 4.2 %. 
Univariate analysis revealed acute type A dissection, endocarditis and emergency 
operation as significant variables for hospital mortality. 
Follow-up results were unsatisfactory. During a mean follow-up of 3.1 years the 
mortality was 33.1 % of the hospital survivors and the number of endocarditis of 
the Shelhigh bioconduit (7.3 %) was higher compared to our aortic homograft series 
and to other stentless biological conduits (44, 47, 48). In addition, the percentage of 
patients with sudden, unexplained death (9.3 %) was also high. Endocarditis of the 
Shelhigh bioconduit among these sudden, unexplained deaths could not be ruled out.
After several warnings, the US Food and Drug Administration (FDA) published a 
preliminary public health notification on possible contamination and malfunction of 
devices manufactured by Shelhigh Inc in 2007 (49). The FDA recommended a voluntary 
recall, but the company declined, after which the FDA seized all medical products from 
the device manufacturer. Soon after this Carrel and associates reported a worrying 
rate of deleterious outcome (50). They experienced “sudden disastrous findings” in 
6.1 % of their Shelhigh bioconduit group with disintegration of the graft and rupture 
of the aortic root. Although they could not find any causative microorganism, their 
patients experienced persistent fever or subfebrile temperatures for months. In our 
Shelhigh group microorganisms were isolated from blood cultures or tissue material 
collected during reoperation. Carrel and associates described a brownish gelatinous 
material at the native annulus during reoperation and we also had a comparable 
observation during reoperation. 
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Beside these two reports with unsatisfactory experiences with the Shelhigh 
bioconduit, there were also two reports with satisfactory results (51, 52). Musci and 
associates reported a reinfection after Shelhigh implantation of 8.6 % in a group of 
255 endocarditis patients of which 26 received a Shelhigh bioconduit and the other 
patients a Shelhigh aortic bioprosthesis (51). There was no specification whether the 
reinfection cases were Shelhigh conduits or bioprostheses. They concluded that their 
reinfection rate is comparable to the results achieved with their treatment of aortic 
valve endocarditis with cryopreserved homografts. In our series, the aortic homografts 
had a lower reinfection rate (3.2 %) compared to our Shelhigh bioconduits (7.3 %). 
Galinanes and associates reported two (3.0 %) reinfections after Shelhigh bioconduit 
implantation from a total group of 67 implantations with a mean follow-up of 7.1 
years (52). They did not show an increased endocarditis rate after implantation of a 
Shelhigh conduit. Consequently, it is debatable whether the bioconduit is the cause 
of endocarditis or if other factors play a role, such as patient-related mechanisms 
(inflammatory reaction), operation-related factors (use of glue) or other variables. 
Unfortunately, based on our results and those from the literature the answer remains 
unclear and more studies are needed from centres with their Shelhigh bioconduit 
experiences. 
Based on our follow-up results with the Shelhigh bioconduit we have stopped using 
this bioconduit for aortic root reconstruction. Patients with a Shelhigh bioconduit are 
closely monitored with repeat computed tomography scans and/or echocardiographic 
evaluation.
As a successor to the Shelhigh bioconduit the BioValsalva conduit was introduced 
as a biological valved conduit for different aortic root pathology in the elderly. This 
conduit consists of a stentless porcine valve incorporated in a triple layered Valsalva 
prosthetic graft with a sinus-like shape at the proximal part of the prosthetic graft. 
Chapter 8 presents our initial experience with this new conduit. Hospital mortality 
was comparable to other reports on this conduit and satisfactory in a patient group 
with a mean age of 70.9 years and 25.5 % of the aortic root replacements being a 
reoperation after previous cardiac surgery (53-56). During implantation of this conduit 
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it is important to measure the appropriate location for the coronary ostia because 
of the position of commissures of the stentless porcine valve. The opening for the 
coronary ostia should be made with a blade and a punch and not with electrocautery, 
because of the polytetrafluoroethylene (PTFE) outer layer, as recommended by the 
manufacturer. Despite this there have been few reported cases of blood between 
the Dacron inner layer and the PTFE outer layer mimicking a dissection (57-59). 
Their hypotheses was that the dissection may have been caused by separation of the 
layers when a scalpel has been used for coronary ostia openings. They recommended 
soldering the layers together at the coronary button openings with electrocautery. To 
date, we have followed the recommendations of the manufacturer and have not seen 
this complication, but it is something to be aware of in a triple-layered graft. 
During follow-up the reoperation rate was low (2.1 %). Both patients were reoperated 
on because of endocarditis of the BioValsalva conduit and survived. In one patient the 
affected stentless porcine valve in the BioValsalva conduit could be replaced without 
removing the entire BioValsalva conduit. This illustrates the possibility for aortic valve 
re-replacement of a degenerated porcine valve in a BioValsalva conduit. Baraki and 
associates have demonstrated the surgical feasibility of aortic valve re-replacement 
in sheep after a BioValsalva conduit implantation (60). They found slight adhesions of 
the vascular prosthesis to the surrounding tissue. They concluded that a degenerated 
stentless biological valve inside the BioValsalva conduit could be replaced with a 
new tissue valve, without having to remove the entire conduit. We also observed 
slight adhesions during aortic valve re-reoperation on a BioValsalva conduit. This is 
advantageous compared to a calcified homograft often found during reoperation. For 
relatively young patients (> 50 years) who want to avoid the drawbacks of systemic oral 
anticoagulation and accept the risk of a reoperation, the BioValsalva conduit can be an 
option. When the stentless valve of the BioValsalva is degenerated and the patient is 
suitable for a reoperation, this patient can then have a less extensive reoperation by 
only replacing the biological aortic valve. 
Our preliminary results with the BioValsalva conduit are satisfactory. During the 
initial short follow-up period the reoperation rate is low. Valve failure in a BioValsalva 
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conduit can be resolved by replacement of the porcine valve only, without having to 
remove the whole conduit, which is advantageous. Follow-up is mandatory as long-
term results of the BioValsalva conduit are awaited.
CONCLUSIONS 
Based on mid-term follow-up results, aortic homografts are no longer recommended 
to young patients (< 65 years) with aortic root disease. In aortic valve endocarditis the 
indication to use a homograft is limited to endocarditis with annular abscesses only. 
Long-term follow-up is necessary to draw final conclusions and to clarify the use of 
aortic homografts in the future. 
Young patients with aortic root disease and the desire not to use oral anticoagulation 
have the option of undergoing a modified Ross procedure. Mid-term results justify the 
use of this procedure, but the autograft needs an annular or sinotubular reinforcement 
in order to reduce the reoperation risk. Further follow-up is needed to elucidate the 
long-term durability of the autograft and the pulmonary homograft. 
In some pathological conditions of the aortic root the aortic leaflets may be preserved. 
These preserved aortic leaflets can be spared by using the reimplantation technique. 
Mid-term evaluation of this technique encourages its use in aortic root aneurysms, 
aortic dissections and Marfan patients with aortic root aneurysms. Long-term results 
are awaited.
Commercially available stentless biological valved conduits are known for their good 
hemodynamic features. Our experience with the totally biological Shelhigh conduit 
had unsatisfactory follow-up results with a relatively high rate of follow-up mortality 
and endocarditis. We have therefore stopped using this bioconduit for aortic root 
reconstruction and patients with a Shelhigh bioconduit are closely monitored.
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The BioValsalva conduit is the successor of the Shelhigh bioconduit and is a unique 
combination of porcine biological leaflets in a triple layered vascular graft. The 
preliminary results with the BioValsalva conduit are promising and further follow-up is 
needed for long-term evaluation.
Chapter 9
136
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
REFERENCES
1. Anderson RH. Clinical anatomy of the aortic root. Heart 2000;84:670–3.
2. McGiffin DC, Galbraith AJ, McLachlan GJ, Stower RE, Wong ML, Stafford EG, et al. Aortic 
valve infection. Risk factors for death and recurrent endocarditis after aortic valve 
replacement. J Thorac Cardiovasc Surg 1992;104:511-20.
3. Haydock D, Barrat-Boyes B, Macedo T, Kirklin JW, Blackstone E. Aortic valve replacement 
for active infectious endocarditis in 108 patients. A comparison of freehand allograft valves 
with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1992;103:130-
9.
4. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al. Treatment of 
endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. 
Ann Thorac Surg 2001;71:1164-71.
5. Newton S, Hunter S. What type of valve replacement should be used in patients with 
endocarditis? Interact Cardiovasc Thorac Surg 2010;11:784-8.
6. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treatment 
of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg 
2007;133:144-9.
7. Delay D, Pellerin M, Carrier M, Marchand R, Auger P, Perrault LP, et al. Immediate and 
long-term results of valve replacement for native and prosthetic valve endocarditis. Ann 
Thorac Surg 2000;70:1219-23.
8. Nguyen DT, Delahaye F, Obadia JF, Duval X, Selton-Suty C, Carteux JP, et al. Aortic valve 
replacement for active infective endocarditis: 5-year survival comparison of bioprostheses, 
homografts and mechanical prostheses. Eur J Cardiothorac Surg 2010;37:1025-32.
9. Klieverik LM, Yacoub MH, Edwards S, Bekkers JA, Roos-Hesselink JW, Kappetein AP, 
Takkenberg JJ, Bogers AJ. Surgical treatment of active native aortic valve endocarditis 
with allografts and mechanical prostheses. Ann Thorac Surg 2009;88:1814-21.
10. Jassar AS, Bavaria JE, Szeto WY, Moeller PJ, Maniaci J, Milewski RK, et al. Graft selection for 
aortic root replacement in complex active endocarditis: does it matter? Ann Thorac Surg 
2012;93:480-7.
11. Musci M, Weng Y, Hubler M, Amiri A, Pasic M, Kosky S, et al. Homograft aortic root 
replacement in native or prosthetic active infective endocarditis: twenty-year single-
center experience. J Thorac Cardiovasc Surg 2010;139:665-73.
12. Sabik JF, Lytle BW, Blackstone EH, Marullo AG, Pettersson GB, Cosgrove DM. Aortic root 
replacement with cryopreserved allograft for prosthetic valve endocarditis. Ann Thorac 
Surg 2002;74:650-9. 
13. Gulbins H, Kilian E, Roth S, Uhlig A, Kreuzer E, Reichart B. Is there an advantage in using 
homografts in patients with acute infective endocarditis of the aortic valve? J Heart Valve 
Dis 2002;11:492-7.
14. O’Brien MF, Harrocks S, Stafford EG, Gardner MA, Pohlner PE, Tesar PJ, et al. The 
homograft aortic valve: a 29-year, 99.3% follow-up of 1,022 valve replacements. J Heart 
Valve Dis 2001;10:334-44; discussion 335.
15. Lund O, Chandrasekaran V, Grocott-Mason R, Elwidaa H, Mazhar R, Khagani A, et al. 
Primary aortic valve replacement with allografts over twenty-five years: valve-related and 
procedure-related determinants of outcome. J Thorac Cardiovasc Surg 1999;117:77-90; 
discussion 90-1.
Discussion
137
9
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
16. El-Hamamsy I, Eryigit Z, Stevens LM, Sarang Z, George R, Clark L, et al. Long-term 
outcomes after autograft versus homograft aortic root replacement in adults with aortic 
valve disease: a randomised controlled trial. Lancet 2010 14;376(9740):524-31.
17. Malvindi PG, van Putte BP, Leone A, Heijmen RH, Schepens MA, Morshuis WJ. Aortic 
reoperation after freestanding homograft and pulmonary autograft root replacement. 
Ann Thorac Surg 2011;91:1135-40.
18. Bekkers JA, Klieverik LM, Bol Raap G, Takkenberg JJ, Bogers AJ. Re-operations for aortic 
allograft root failure: experience from a 21-year single center follow-up study. Eur J 
Cardiothor Surg 2011;40:35-42.
19. Nowicki ER, Petterson G, Smedira NG, Roselli EE, Blackstone EH, Lytle BW. Aortic allograft 
valve reoperation: surgical challenges and patient risks. Ann Thorac Surg 2008;86:761-
768.
20. Bekkers JA, Klieverik LM, Bol Raap G, Takkenberg JJ, Bogers AJ. Aortic root reoperations 
after pulmonary autograft implantation. J Thorac Cardiovasc Surg 2010;140:S58-63.
21. David TE, Omran A, Webb G, Rakowski H, Armstrong S, Sun Z. Geometric mismatch of the 
aortic and pulmonary roots causes aortic insufficiency after the Ross procedure. J Thorac 
Cardiovasc Surg 1996;112:1231-7.
22. Elkins RC, Knott-Craig CJ, Howell CE. Pulmonary autografts in patients with aortic annulus 
dysplasia. Ann Thorac Surg 1996;61:1141-5.
23. Charitos EI, Hanke T, Stierle U, Robinson DR, Bogers AJ, Hemmer W, et al. Autograft 
reinforcement to preserve autograft function after the Ross procedure: a report from the 
German-Dutch Ross registry. Circulation 2009;120:S146-54.
24. Sievers HH, Stierle U, Charitos EI, Hanke T, Misfeld M, Bechtel JF, et al. Major adverse and 
cardiac events after the Ross procedure: a report from the German-Dutch Ross registry. 
Circulation 2010;122:S216-23.
25. Miller DC. Valve-sparing aortic root replacement in patients with the Marfan syndrome. J 
Thorac Surg 2003;125:773-8.
26. Grande-Allen KJ, Cochran RP, Reinhall PG, Kunzelman KS. Re-creation of sinuses is 
important for sparing the aortic valve: a finite element study. J Thorac Cardiovasc Surg 
2000;119:753-63.
27. Beck A, Thubrikar MJ, Robiscek F. Stress analysis of the aortic valve with and without the 
sinuses of valsalva. J Heart Valve Dis 2001;10:1-11.
28. Schoenhoff FS, Loupatatzis C, Immer FF, Stoupis C, Carrel TP, Eckstein FS. The role of the 
sinuses of valsalva in aortic root flow dynamics and aortic root surgery: evaluation by 
magnetic resonance imaging. J Heart Valve Dis 2009;18:380-5.
29. Weltert L, De Paulis R, Scaffa R, Maselli D, Bellisario A, D’Allesandro S. Re-creation of 
a sinuslike graft expansion in Bentall procedures reduces stress at the coronary button 
anastomosis: a finite element study. J Thorac Cardiovasc Surg 2009;137:1082-7.
30. Subramanian S, Leontyev S, Borger MA, Trommer C, Misfield M, Mohr FW. Valve-sparing 
root reconstruction does not compromise survival in acute type A aortic dissection. Ann 
Thorac Surg 2012;94:1230-4.
31. Valo J, Jokinen JJ, Kaarne M, Ihlberg L. Expanding indications for valve-sparing aortic root 
reconstruction: early and midterm results. Ann Thorac Surg 2013;95(2):579-85.
32. Kallenbach K, Pethiq K, Leyh RG, Baric D, Haverich A, Harringer W. Acute dissection of the 
ascending aorta: first results of emergency valve sparing aortic root reconstruction. Eur J 
Cardiothorac Surg 2002;22(2):218-21. 
Chapter 9
138
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
33. Erasmi AW, Stierle U, Bechtel JF, Schmidtke C, Sievers HH, Kraatz EG. Up to 7 years’ 
experience with valve-sparing aortic root remodeling/reimplantation for acute type A 
dissection. Ann Thorac Surg 2003;76(1):99-104.
34. Kerendi F, Guyton RA, Vega JD, Kilgo PD, Chen EP. Early results of valve-sparing aortic root 
replacement in high-risk clinical scenarios. Ann Thorac Surg 2010;89(2):471-6.
35. David TE, Armstrong S, Maganti M, Colman J, Bradley T. Long-term results of aortic 
valve-sparing operations in patients with Marfan syndrome. J Thorac Cardiovasc Surg 
2009;138:859-64.
36. Kallenbach K, Baraki H, Khaladj N, Kamiya H, Hagl C, Haverich A, et al. Aortic valve-sparing 
operation in Marfan syndrome: what do we know after a decade? Ann Thorac Surg 
2007;83:S764-8.
37. Settepani F, Szeto WY, Pacini D, De Paulis R, Chiariello L, Di Bartolomeo R, et al. 
Reimplantation valve-sparing aortic root replacement in Marfan syndrome using the 
Valsalva conduit: an intercontinental multicenter study. Ann Thorac Surg 2007;83:S769-
73. 
38. David TE, Maganti M, Armstrong S. Aortic root aneurysm: principles of repair and long-
term follow-up. J Thorac Cardiovasc Surg 2010;140:S14-9.
39. De Paulis R, Scaffa R, Nardella S, Maselli D, Weltert L, Bertoldo F, Pacini D, Settepani F, 
Tarelli G, Gallotti R, Di Bartolomeo R, Chiariello L. Use of the Valsalva graft and long-term 
follow-up. J Thorac Cardiovasc Surg 2010;140:S23-7.
40. Shrestha M, Baraki H, Maeding I, Fitzner S, Sarikouch S, Khaladj N, Hagl C, Haverich A. 
Long-term results after aortic valve-sparing operation (David I). Eur J Cardiothorac Surg 
2012;41:56-62.
41. Leontyev S, Trommer C, Subramanian S, Lehmann S, Dmitrieva Y, Misfeld M, Mohr FW, 
Borger MA. The outcome after aortic valve-sparing (David) operation in 179 patients : a 
single-centre experience. Eur J Cardiothorac Surg 2012 ;42 :261-6. 
42. Gross C, Harringer W, Beran H, Mair R, Sihorsch K, Hofmann R, Brucke P. Aortic valve 
replacement: is the stentless xenograft an alternative to the homograft? Midterm results. 
Ann Thorac Surg 1999;68:919–924.
43. Dagenais F, Cartier P, Voisine P, Desaulniers D, Perron J, Baillot R, et al. Which biological 
valve should we select for the 45- to 65-year-old age group requiring aortic valve 
replacement. J Thorac Cardiovasc Surg 2005;129:1041-9.
44. El-Hamamsy I, Clark L, Stevens LM, Sarang Z, Melina G, Takkenberg JJ, Yacoub MH. Late 
outcomes following freestyle versus homograft aortic root replacement: results from a 
prospective randomized trial. J Am Coll Cardiol 2010;55:368-76.
45. Siniawski H, Lehmkuhl H, Weng Y, Pasic M, Yankah C, Hoffmann M, et al. Stentless 
aortic valves as an alternative to homografts for valve replacement in active infective 
endocarditis complicated by ring abscess. Ann Thorac Surg 2003;75:803–8.
46. Carrel TP, Berdat P, Englberger L, Eckstein F, Immer F, Seiler C, et al. Aortic root replacement 
with a new stentless aortic valve xenograft conduit: preliminary hemodynamic and clinical 
results. J Heart Valve Dis 2003;12:752-7.
47. LeMaire SA, Green SY, Sharma K, Cheung CK, Sameri A, Tsai PI, et al. Aortic root 
replacement with stentless porcine xenografts: early and late outcomes in 132 patients. 
Ann Thorac Surg 2009;87:503–13.
48. Dapunt OE, Easo J, Hölzl P, Murin P, Südkamp M, Horst M, et al. Stentless full root 
bioprosthesis in surgery for complex aortic valve-ascending aortic disease: a single center 
experience of over 300 patients. Eur J Cardiothorac Surg 2008;33:554-9.
Discussion
139
9
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
49. FDA preliminary public health notification: possible contamination and malfunction of 
heart valves and valved conduits, annuloplasty rings, surgical grafts, meshes and other 
devices manufactured by Shelhigh, Inc. April 18, 2007. Available at: www.fda.gov/cdrh/
safety/041807- shelhigh.html. Accessed Aug 22, 2007.
50. Carrel TP, Schoenhoff FS, Schmidli J, Stalder M, Eckstein FS, Englberger L. Deletrious 
outcome of No-React-treated stentless valved conduits after aortic root replacement: 
why were warnings ignored? J Thorac Cardiovasc Surg 2008;136:52-7.
51. Musci M, Siniawski H, Pasic M, Weng Y, Loforte A, Kosky S, Yankah C, Hetzer R. Surgical 
therapy in patients with active infective endocarditis: seven-year single center experience 
in a subgroup of 255 patients treated with the Shelhigh stentless bioprosthesis. Eur J 
Cardiothorac Surg 2008;34:410-7.
52. Galinanes M, Meduoye A, Ferreira I, Sosnowski A. Totally biological composite aortic 
stentless valved conduit for aortic root replacement: 10-year experience. J Cardiothorac 
Surg 2011;6:86.
53. Baraki H, Al Ahmad A, Sarikouch S, Koigeldiev N, Khaladj N, Hagl C, et al. The first fifty 
consecutive Bentall operations with a prefabricated tissue-valved aortic conduit: a single-
center experience. J Heart Valve Dis. 2010;19:286-91.
54. Di Bartolomeo R, Botta L, Leone A, Pilato E, Martin-Suarez S, Bacchini M, et al. BioValsalva 
prosthesis: ‘new’ conduit for ‘old’ patients. Interact Cardiovasc Thorac Surg 2008;7:1062-
6.
55. Moorjani N, Modi A, Mattam K, Barlow C, Tsang G, Haw M, et al. Aortic root replacement 
using a biovalsalva prosthesis in comparison to a “handsewn” composite bioprosthesis. J 
Card Surg 2010;25:321-6.
56. Lau KK, Bochenek-Klimczyk K, Galinanes M, Sosnowski AW. Replacement of the ascending 
aorta, aortic root, and valve with a novel stentless valved conduit. Ann Thorac Surg 
2008;86:278-81.
57. Tan ME, ter Woorst FJ, Elenbaas TW, van Straten AH. Dissected biovalsalva prosthesis. Eur 
J Cardiothorac Surg 2009;36:400.
58. Cochron S, Kaili D. Re: dissected biovalsalva prosthesis. Eur J Cardiothorac Surg 
2010;37:980.
59. Yigzaw YA, Lau KK, Baig K, Uppal R. Chronic dissection and aneurysmal dilatation of a 
BioValsalva conduit. Ann Thorac Surg 2013;96:298-300.
60. Baraki H, Tudorache I, Hoeffler K, Khaladj N, Hagl C, Cebotari S, et al. Aortic valve re-
replacement after Bentall procedure with a biological valved conduit in a sheep model. J 
Heart Valve Dis. 2012;21:5-11.

10
Summary
Chapter 10
142
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
Summary
143
10
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
In Chapter 1 a general introduction is given. The functional anatomy, the most common 
aortic root disease and various options for biological valved aortic root reconstruction 
is described and the aim of the thesis is outlined.
Chapter 2 reports the follow-up results of aortic root replacement with an aortic 
homograft in 213 patients. During a mean follow-up of almost 6 years 10.3 % of the 
hospital survivors died and a fourth of these were valve-related late deaths. Structural 
valve deterioration was the predominant cause of reoperation. The incidence of 
endocarditis of the homograft was studied and echocardiographic assessment of 
aortic homograft function was analyzed.
Chapter 3 discusses the results of aortic root replacement with the pulmonary 
autograft in 103 adult patients. Mid-term follow-up showed an excellent overall 
survival. Dilatation of the autograft was the primary cause of reoperation and 
reinforcement of the autograft is discussed. Autograft valve function was analyzed by 
echocardiography and majority of patients had no or trivial aortic regurgitation. The 
importance of periodic echocardiographic evaluation of the autograft is illustrated in 
Chapter 4. It describes a rare case of a chronic type A aortic dissection in a pulmonary 
autograft.
 
Chapter 5 is a retrospective analysis of valve-sparing aortic root replacement using the 
reimplantation technique in 81 consecutive patients between 1998 and 2010. There 
was no hospital mortality. Follow-up mortality (11.1 %) was studied and was mainly 
due to neoplasm. During follow-up, the incidence of reoperation (11.1 %) was studied 
as well as the incidence of endocarditis (2.5 %) and echocardiographic imaging was 
evaluated. A rare case of valve-sparing surgery is illustrated in Chapter 6 in which a 
traumatic lesion of the left coronary cusp is repaired.
Chapter 7 evaluates the initial experience with the totally biological Shelhigh 
bioconduit. Aneurysmal disease of the aorta was the primary indication for aortic 
root replacement. Hospital and follow-up mortality were studied. The incidence 
of reoperation and endocarditis of the Shelhigh bioconduit during follow-up were 
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shown. Notable was the follow-up mortality (33.1 %) and the endocarditis rate (7.3 
%) of this bioconduit. 
Chapter 8 describes the results with the Biovalsalva conduit for aortic root replacement 
in 102 patients. The predominant use of this conduit was for aneurysmal disease of 
the aorta. Overall hospital mortality was 4.9 % and for elective procedures this was 3.3 
%. Follow-up showed a reoperation rate of 2.1 % and endocarditis of the Biovalsalva 
conduit was observed in 3.1 %. Further follow-up is necessary. 
Chapter 9 provides a general discussion. 
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Hoofdstuk 1 geeft een algemene inleiding. De functionele anatomie van de aortawortel, 
meest voorkomende pathologie en verschillende biologische alternatieven voor 
aortawortelvervanging worden besproken en het doel van de dissertatie wordt 
uiteengezet.
Hoofdstuk 2 beschrijft de follow-up resultaten van aortawortelvervanging door 
middel van een menselijk donor aortaklep in 213 patiënten. Gedurende een 
gemiddelde follow-up van bijna 6 jaar stierven 10.3 % van de ziekenhuis overlevenden 
en een vierde daarvan waren klepgerelateerde sterfgevallen. Structureel klep falen 
van de donor aortaklep was de voornaamste oorzaak van reoperatie. De incidentie 
van endocarditis van de donor aortaklep werd bestudeerd en het echocardiografisch 
functioneren van de donor aortaklep werd onderzocht.
In Hoofdstuk 3 worden de resultaten van het gebruik van de pulmonalis autograft voor 
aortawortelvervanging in 103 volwassen patiënten geëvalueerd. Mid termijn follow-
up liet een uitstekende overleving zien. De voornaamste oorzaak voor reoperatie 
was dilatatie van de pulmonalis autograft en versteviging van de autograft wordt 
bediscussieerd. Autograft klepfunctie werd geanalyseerd middels echocardiografie 
en de meerderheid van de patiënten had geen of triviale regurgitatie. Het belang 
van periodieke echocardiografische evaluatie van de pulmonalis autograft wordt 
geïllustreerd in Hoofdstuk 4, waarin een zeldzaam geval van chronisch type A dissectie 
in de pulmonalis autograft wordt beschreven. 
Hoofdstuk 5 is een retrospectieve analyse van klepsparende aortawortelvervanging 
met de reimplantatie techniek in 81 opeenvolgende patiënten tussen 1998 en 2010. 
Er was geen ziekenhuissterfte. Follow-up mortaliteit (11.1 %) werd onderzocht en was 
voornamelijk door een neoplasma. Gedurende de follow-up werd de incidentie van 
reoperatie (11.1 %) en endocarditis (2.5 %) onderzocht en de echocardiografische 
resultaten geëvalueerd. Een zeldzame casus van klepsparende chirurgie wordt in 
Hoofdstuk 6 geïllustreerd, waarin een traumatisch laesie van de linker coronaire cusp 
is gerepareerd.
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Hoofdstuk 7 evalueert de initiële ervaringen met de volledig biologische Shelhigh 
bioconduit. Aneurysmata van de aortawortel waren de voornaamste indicaties voor 
aortawortelvervangingen. Ziekenhuis en follow-up mortaliteit werd onderzocht. De 
incidentie van reoperatie en endocarditis van de Shelhigh bioconduit werd getoond. 
Opvallend was de follow-up mortaliteit (33.1 %) en de endocarditis percentage (7.3 
%) van deze bioconduit. 
Hoofdstuk 8 beschrijft de resultaten met de Biovalsalva conduit voor 
aortawortelvervanging in 102 patiënten. De voornaamste indicatie voor gebruik van 
deze conduit was een aneurysma van de aortawortel. Algehele ziekenhuissterfte was 
4.9 % en voor electieve procedures was dit 3.3 %. Follow-up toonde een reoperatie 
percentage van 2.1 % en endocarditis van de Biovalsalva conduit werd geobjectiveerd 
bij 3.1 %. Verder follow-up is noodzakelijk. 
Hoofdstuk 9 bevat een algemene discussie. 
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